
*J. Am. Coll. Cardiol.* 2009;54;2205-2241; originally published online Nov 18, 2009;
doi:10.1016/j.jacc.2009.10.015

This information is current as of December 2, 2009

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://content.onlinejacc.org/cgi/content/full/54/23/2205
FOCUSED UPDATE


A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Frederick G. Kushner, MD, FACC, FAHA, FSCAI, Co-Chair; Mary Hand, MSPH, RN, FAHA, Co-Chair*

Sidney C. Smith, Jr, MD, FACC, FAHA, Chair; Spencer B. King III, MD, MACC, FSCAI, Co-Chair;

Jeffrey L. Anderson, MD, FACC, FAHA; Elliott M. Antman, MD, FACC, FAHA;

Steven R. Bailey, MD, FACC, FSCAI; Eric R. Bates, MD, FACC, FAHA;

James C. Blankenship, MD, FACC, FSCAI; Donald E. Casey, Jr, MD, MPH, MBA;

Lee A. Green, MD, MPH; Judith S. Hochman, MD, FACC, FAHA;

Alice K. Jacobs, MD, FACC, FAHA, FSCAI; Harlan M. Krumholz, MD, SM, FACC, FAHA;

Douglass A. Morrison, MD, PhD, FACC, FSCAI; Joseph P. Ornato, MD, FACC, FAHA;

David L. Pearle, MD, FACC, FAHA; Eric D. Peterson, MD, MPH, FACC, FAHA;

Michael A. Sloan, MD, MS, FACC, FAHA; Patrick L. Whitlow, MD, FACC, FAHA;

David O. Williams, MD, FACC, FAHA, FSCAI

*The opinions expressed in this article should not be construed as necessarily representing an official position of the US Department of Health and Human Services, the Agency for Healthcare Research and Quality, or the US Government, by whom M. Hand is employed.

†Recused from Section 3, Thienopyridines; Section 4, Parenteral Anticoagulants; Section 5, Triage and Transfer for PCI.

‡Recused from Section 3, Thienopyridines; Section 4, Parenteral Anticoagulants.

§Recused from Section 6, Intensive Glucose Control.

¶Recused from Section 2, Glycoprotein IIb/IIIa Receptor Antagonists; Section 3, Thienopyridines.

#Recused from Section 3, Thienopyridines; Section 7, Thrombus Aspiration; Section 8, Use of Stents; Section 11, PCI for Left Main Coronary Artery Disease.

**Recused from Section 3, Thienopyridines.

††Society for Cardiovascular Angiography and Interventions Representative.

‡‡Recused from Section 10, Fractional Flow Reserve.

§§Recused from Section 3, Thienopyridines; Section 5, Triage and Transfer for PCI; Section 8, Use of Stents.

||Former Task Force member during this writing effort.

This document was approved by the American College of Cardiology Foundation Board of Trustees in September 2009, by the American Heart Association Science Advisory and Coordinating Committee in September 2009, and by the Society for Cardiovascular Angiography and Interventions Board of Trustees in October 2009.


This article has been copublished in Circulation and Catheterization and Cardiovascular Interventions.

Copies: This document is available on the World Wide Web sites of the American College of Cardiology (www.acc.org), the American Heart Association (my.americanheart.org), and the Society for Cardiovascular Angiography and Interventions (scai.org). For copies of this document, please contact Elsevier Inc. Reprint Department, fax 212-633-3820, e-mail reprints@elsevier.com.

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American College of Cardiology Foundation. Please contact Elsevier’s permission department at healthpermissions@elsevier.com.
TABLE OF CONTENTS

2009 STEMI and PCI Focused Updates ............. 2207

Preamble ..................................... 2207
1. Introduction ................................ 2209
   1.1. Methodology and Evidence Review .... 2209
   1.2. Organization of Committee and Relationships With Industry and Other Entities 2209
   1.3. Document Review and Approval ........ 2210

2. Recommendations for the Use of Glycoprotein IIb/IIIa Receptor Antagonists .... 2210
   2.1. Glycoprotein IIb/IIIa Receptor Antagonists .................. 2210

3. Recommendations for the Use of Thienopyridines .......... 2211
   3.1. Thienopyridines ....................... 2211
   3.1.1. Additional Thienopyridine Information .......... 2215
   3.1.2. Choice of Thienopyridine for PCI in STEMI ............. 2215

   3.2. Proton Pump Inhibitors and Dual-Antiplatelet Therapy for ACS ............. 2215

4. Recommendations for the Use of Parenteral Anticoagulants ........ 2216
   4.1. Parenteral Anticoagulants .................. 2216

5. Recommendations for Triage and Transfer for PCI .................. 2217
   5.1. Triage and Transfer for PCI ............... 2217
   5.1.1. STEMI Patients Who Are Candidates for Reperfusion .................. 2217

6. Recommendations for Intensive Glucose Control in STEMI ............. 2220
   6.1. Intensive Glucose Control .................. 2221

7. Recommendation for Thrombus Aspiration During PCI for STEMI ............. 2221
   7.1. Thrombus Aspiration ........................ 2222

8. Recommendations for the Use of Stents in STEMI ............. 2222
   8.1. Stent Selection for STEMI .................. 2222

PCI Focused Update Section ..................... 2223

9. Recommendation for Angiography in Patients With Chronic Kidney Disease ............. 2223
   9.1. Angiography in Patients With Chronic Kidney Disease .................. 2223

10. Recommendations for Use of Fractional Flow Reserve ............. 2224
    10.1. Fractional Flow Reserve .................. 2224

11. Recommendations for PCI for Unprotected Left Main Coronary Artery Disease ............. 2224
    11.1. Unprotected Left Main Coronary Artery Disease .................. 2224

12. Recommendations for the Timing of Angiography and Antiplatelet Therapy in UA/NSTEMI ............. 2226
    12.1. Timing of Angiography .................. 2226
    12.2. Timing of GP IIb/IIIa Receptor Antagonist Therapy in UA/NSTEMI Patients Undergoing Angiography .................. 2227

Appendix 1. Author Relationships With Industry and Other Entities—ST-Elevation Myocardial Infarction ............. 2229
Appendix 2. Author Relationships With Industry and Other Entities—Percutaneous Coronary Intervention ........................................... 2230

Appendix 3. Reviewer Relationships With Industry and Other Entities—2009 STEMI and PCI Focused Updates ........................................... 2231

Appendix 4. Dosing Table for Antiplatelet and Anticoagulant Therapy Discussed in This Focused Update to Support PCI in STEMI ........................................... 2234

Appendix 5. Triage and Transfer for PCI ........................................... 2236

Appendix 6. Outcomes of PCI Versus CABG for Unprotected Left Main Coronary Artery Disease ........................................... 2236

References ........................................... 2237

2009 STEMI and PCI Focused Updates

Preamble

A primary challenge in the development of clinical practice guidelines is keeping pace with the stream of new data on which recommendations are based. In an effort to respond promptly to new evidence, the American College of Cardiology Foundation/American Heart Association (ACCF/AHA) Task Force on Practice Guidelines has created a “focused update” process to revise the existing guideline recommendations that are affected by evolving data or opinion. Before the initiation of this focused approach, periodic updates and revisions of existing guidelines required up to 3 years to complete. Now, however, new evidence will be reviewed in an ongoing fashion to more efficiently respond to important science and treatment trends that could have a major impact on patient outcomes and quality of care. Evidence will be reviewed at least twice a year, and updates will be initiated on an as-needed basis as quickly as possible, while maintaining the rigorous methodology that the ACCF and AHA have developed during their 25 years of partnership.

These updated guideline recommendations reflect a consensus of expert opinion after a thorough review primarily of late-breaking clinical trials identified through a broad-based vetting process as being important to the relevant patient population, as well as a review of other new data deemed to have an impact on patient care (see Section 1.1, Methodology and Evidence Review, for details). This focused update is not intended to represent an update based on a full literature review from the date of the previous guideline publication. Specific criteria/considerations for inclusion of new data include the following:

- publication in a peer-reviewed journal;
- large randomized, placebo-controlled trial(s);
- nonrandomized data deemed important on the basis of results that affect current safety and efficacy assumptions;
- strength/weakness of research methodology and findings;
- likelihood of additional studies influencing current findings;
- impact on current performance measure(s) and/or likelihood of need to develop new performance measure(s);
- requests and requirements for review and update from the practice community, key stakeholders, and other sources free of relationships with industry or other potential bias;
- number of previous trials showing consistent results; and
- need for consistency with a new guideline or guideline revision.

In analyzing the data and developing updated recommendations and supporting text, the focused update writing group used evidence-based methodologies developed by the ACCF/AHA Task Force on Practice Guidelines, which are described elsewhere (1).

The schema for classification of recommendations and level of evidence is summarized in Table 1, which also illustrates how the grading system provides an estimate of the size of the treatment effect and an estimate of the certainty of the treatment effect. Note that a recommendation with level of evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in guidelines do not lend themselves to clinical trials. Although randomized trials may not be available, there may be a very clear clinical consensus that a particular test or therapy is useful and effective. Both the classification of recommendations and level of evidence listed in the focused updates are based on consideration of the evidence reviewed in previous iterations of the guideline and the focused update. Of note, the implications of older studies that have informed recommendations but have not been repeated in contemporary settings are considered carefully.

The ACCF/AHA practice guidelines address patient populations (and healthcare providers) residing in North America. As such, drugs that are not currently available in North America are discussed in the text without a specific class of recommendation. For studies performed in large numbers of subjects outside of North America, each writing group reviews the potential impact of different practice patterns and patient populations on the treatment effect and on the relevance to the ACCF/AHA target population to determine whether the findings should inform a specific recommendation.

The ACCF/AHA practice guidelines are intended to assist healthcare providers in clinical decision making by describing a range of generally acceptable approaches for the diagnosis, management, and prevention of specific diseases or conditions. The guidelines attempt to define practices that meet the needs of most patients in most circumstances. The ultimate judgment regarding care of a particular patient must be made by the healthcare provider and patient in light of all the circumstances presented by that patient. Thus, there are circumstances in which deviations from these guidelines may be appropriate. Clinical decision making should consider the quality and availability of expertise in the area where care is provided. These guidelines may be used as the basis for regulatory or payer decisions, but the ultimate goals are quality of care and serving the patient’s best interests.

Prescribed courses of treatment in accordance with these recommendations are effective only if they are followed by the patient. Because a lack of patient adherence may adversely affect treatment outcomes, healthcare providers should engage the patient in active participation with the prescribed treatment.
The ACCF/AHA Task Force on Practice Guidelines makes every effort to avoid actual, potential, or perceived conflicts of interest that may arise as a result of industry relationships or personal interests among the writing committee. Specifically, all members of the writing committee, as well as reviewers of the document, are asked to disclose all such relevant relationships pertaining to the trials and other evidence under consideration (see Appendixes 1, 2, and 3). All guideline recommendations require a confidential vote by the writing group and must be approved by a consensus of the members voting. Members who recused themselves from voting are noted on the title page of this document. Members must recuse themselves from voting on any recommendations to which their relationships with industry and other entities apply. Writing group members who did not participate are not listed as authors of this focused update. The work of the writing group was supported exclusively by the ACCF and AHA without commercial support. Writing group members volunteered their time for this effort.

With the exception of the recommendations presented here, the full-text guidelines remain current (2,3). Only the recommendations from the affected section(s) of the full-text guidelines are included in this focused update. Recommendations from any section of a guideline affected by a change are presented with notation as to whether they are new or have been modified; however, recommendations that remain unchanged in each section are not included in this focused update. When evidence affects recommendations in more than 1 set of guidelines, those guidelines are updated concurrently whenever possible.

The recommendations in this focused update will be considered current until they are superseded by another

*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as gender, age, history of diabetes, history of prior myocardial infarction, history of heart failure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even though randomized trials are not available, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.

In 2003, the ACCF/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use when writing recommendations. All guideline recommendations have been written in full sentences that express a complete thought, such that a recommendation, even if separated and presented apart from the rest of the document (including headings above sets of recommendations), would still convey the full intent of the recommendation. It is hoped that this will increase readers’ comprehension of the guidelines and will allow queries at the individual recommendation level.
focused update or the full-text guidelines are revised. This focused update is published in the December 1, 2009, issues of the Journal of the American College of Cardiology and Circulation as an update to the full-text guideline, and it is also posted on the American College of Cardiology (ACC; www.acc.org), AHA (my.americanheart.org), and Society for Cardiovascular Angiography and Interventions (SCAI; scai.org) World Wide Web sites.

Alice K. Jacobs, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines

1. Introduction

1.1. Methodology and Evidence Review

Late-breaking clinical trials presented at the 2007 and 2008 annual scientific meetings of the ACC, AHA, Transcatheter Cardiovascular Therapeutics, the European Society of Cardiology, and the 2009 annual scientific sessions of the ACC were reviewed by the standing guideline writing committee along with the parent Task Force and other experts to identify those trials and other key data that may impact guideline recommendations. On the basis of the criteria/considerations noted above, recent trial data and other clinical information were considered important enough to prompt a focused update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction and the ACC/AHA 2005 Guidelines for Percutaneous Coronary Intervention, inclusive of their respective 2007 focused updates (2–5).

The ST-elevation myocardial infarction (STEMI) and percutaneous coronary intervention (PCI) writing groups together considered the following studies: Two meta-analyses, “A Comparison of Abciximab and Small Molecule Glycoprotein IIB/IIa Inhibitors in Patients Undergoing Primary Percutaneous Coronary Intervention,” (6) and “Benefits From Small Molecule Administration as Compared With Abciximab Among Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Angioplasty,” (7) FINESSE (Facilitated PCI in Patients With ST-Elevation Myocardial Infarction) (8), the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) (9), BRAVE-3 (Bavarian Reperfusion Alternatives Evaluation-3) (10), MULTISTRATEGY (Multicentre Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study) (11), ON-TIME 2 (Ongoing Tirofiban in Myocardial Infarction Evaluation) (12), TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction) (13), TRANSFER-AMI (Trial of Routine ANgioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction) (14), CARESS-in-AMI (Combined Abciximab Reteplase Stent Study in Acute Myocardial Infarction) (15), NICE-SUGAR (Normoglycemia in Intensive Care Evaluation—Survival Using Glucose Algorithm Regulation) (16), TAPAS (Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study) (17), and EXPIRA (Thrombectomy With Export Catheter in Infarct-Related Artery During Primary Percutaneous Coronary Intervention) (18). Additionally, the PCI writing group considered the CARE (Cardiac Angiography in Renally Impaired Patients) (19), FAME (Fractional Flow Reserve versus Angiography for Multivessel Evaluation) study (20), SYNTAX (Synergy Between Percutaneous Intervention With Taxus and Cardiac Surgery) (21), Early ACS (Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes) (22), and TIMACS (Timing of Intervention in Patients With Acute Coronary Syndromes) studies (23). When considering the new data for this focused update, the writing group faced the task of weighing evidence from studies that had enrolled large numbers of subjects outside North America. Although noting that practice patterns and the rigor applied to data collection, as well as the genetic makeup of subjects, may influence the observed magnitude of a treatment’s effect, the writing group believed the data were relevant to the formulation of recommendations for management of STEMI and PCI in North America. The writing group also notes that the AHA/ACC and the Heart Rhythm Society have published updated recommendations for the standardization and interpretation of the electrocardiogram with a separate section on acute ischemia/infarction (24).

To provide clinicians with a comprehensive set of data, whenever possible, the exact event rates in various treatment arms of clinical trials are presented to permit calculation of the absolute risk difference and number needed to treat (NNT) or harm; the relative treatment effects are described either as odds ratio, relative risk (RR), or hazard ratio (HR) depending on the format used in the original publication. Along with all other statistical point estimates, the confidence interval (CI) for those statistics are added when available.

Consult the full-text or executive summary versions of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction or the ACC/AHA/SCAI 2005 Guidelines for Percutaneous Coronary Intervention, as well as their respective 2007 focused updates, for policy on clinical areas not covered by the present focused update (2–5). Unchanged recommendations from previous iterations of the guidelines are not listed in this document and remain current policy. Individual recommendations updated in this focused update will be incorporated into future revisions of the full-text guidelines.

1.2. Organization of Committee and Relationships With Industry and Other Entities

For this focused update, all members of the 2004 STEMI guideline, 2007 STEMI focused update, 2005 PCI guideline, and 2007 PCI focused update writing committees were invited to participate; those who agreed (referred to as the 2009 Focused Update Writing Group) were required to disclose all relationships with industry and other entities relevant to the data under consideration. The policies used for relationships with industry were those in effect at the initial meeting of this committee, which included disclosure of relationships 12 months prior to initiation and a chair with no relevant relationships except in a situation where more than one chair is named. In this circumstance, one chair will have no relevant relationships and the other may have relationships. Each recommendation required a confidential vote by
2009 Focused Updates: STEMI and PCI Guidelines

Table 2. Recommendations for the Use of Glycoprotein IIb/IIIa Receptor Antagonists

<table>
<thead>
<tr>
<th>2004/2005/2007 Recommendations: 2004 STEMI Guideline Section 6.3.1.6.8.2.3; Also 2005 PCI Guideline Section 6.2.2</th>
<th>2009 Joint STEMI/PCI Focused Update Recommendations</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. It is reasonable to start treatment with abciximab as early as possible before primary PCI (with or without stenting) in patients with STEMI. (Level of Evidence: B)</td>
<td>1. It is reasonable to start treatment with glycoprotein IIb/IIIa receptor antagonists (abciximab [9,11], tirofiban [11,12], eptifibatide [6,7,9]) at the time of primary PCI (with or without stenting) in selected patients with STEMI. (Level of Evidence: A)</td>
<td>Modified recommendation (class of recommendation changed from IIb to IIa for tirofiban and eptifibatide).</td>
</tr>
</tbody>
</table>

1. Treatment with tirofiban or eptifibatide may be considered before primary PCI (with or without stenting) in patients with STEMI. (Level of Evidence: C) | 1. The usefulness of glycoprotein IIb/IIIa receptor antagonists (as part of a preparatory pharmacological strategy for patients with STEMI before their arrival in the cardiac catheterization laboratory for angiography and PCI) is uncertain (8,10). (Level of Evidence: B) | Modified recommendation (text modified; level of evidence changed from C to B). |

STEMI and PCI Focused Update Section

2. Recommendations for the Use of Glycoprotein IIb/IIIa Receptor Antagonists

(See Table 2 and Appendix 4.)

2.1. Glycoprotein IIb/IIIa Receptor Antagonists

In considering the use of intravenous glycoprotein (GP) IIb/IIIa receptor antagonists for STEMI, the writing group noted that much of the evidence favoring the use of these agents was established in the era before dual oral antiplatelet therapy and largely by placebo-controlled comparisons. Contemporary management of STEMI patients involves a complex array of antithrombotics, including dual oral antiplatelet therapy (aspirin [acetylsalicylic acid; ASA] plus a thienopyridine) and an anticoagulant. There is a paucity of trials adequately powered for assessment of clinical end points that have reevaluated the current relative role of intravenous GP IIb/IIIa receptor antagonists with respect to other pharmacological therapy in STEMI patients. Accordingly, a reevaluation of the value of GP IIb/IIIa antagonists in STEMI is appropriate, but the ability to draw definitive conclusions is limited.

At least 3 trials evaluated GP IIb/IIIa antagonists as adjuncts to oral antiplatelet therapy in the setting of primary PCI. The findings of these trials question whether GP IIb/IIIa antagonists provide significant additional benefit to STEMI patients who have received dual-antiplatelet therapy before catheterization. In the BRAVE-3 study, 800 patients presenting within 24 hours of a STEMI were pretreated with 600 mg of clopidogrel and then randomly assigned in a double-blind manner to receive either abciximab or placebo in the intensive care unit before being sent for PCI (10). The primary end point was infarct size measured by single photon emission computed tomography before hospital discharge. At 30 days, the composite of death, recurrent myocardial infarction (MI), stroke, or urgent revascularization of the infarct-related artery was not significantly different in the 2 groups (abciximab 5%, placebo 3.8%; 95% CI 0.7 to 2.6; P=0.4). There was no significant difference in infarct size or major bleeding.

ON-TIME 2 was a randomized, placebo-controlled, multicenter European trial that included 491 patients receiving high-dose tirofiban and 493 receiving placebo within a median of 76 minutes from onset of symptoms (12). Patients receiving high-dose tirofiban (25 mcg/kg bolus followed by 0.15 mcg/kg per min for 18 hours) at first medical contact before transport for primary PCI were pretreated with 600 mg of clopidogrel and then randomly assigned in a double-blind manner to receive either abciximab or placebo in the intensive care unit before being sent for PCI (10). The primary end point was infarct size measured by single photon emission computed tomography before hospital discharge. At 30 days, the composite of death, recurrent myocardial infarction (MI), stroke, or urgent revascularization of the infarct-related artery was not significantly different in the 2 groups (abciximab 5%, placebo 3.8%; 95% CI 0.7 to 2.6; P=0.4). There was no significant difference in infarct size or major bleeding.

ON-TIME 2 was a randomized, placebo-controlled, multicenter European trial that included 491 patients receiving high-dose tirofiban and 493 receiving placebo within a median of 76 minutes from onset of symptoms (12). Patients receiving high-dose tirofiban (25 mcg/kg bolus followed by 0.15 mcg/kg per min for 18 hours) at first medical contact before transport for primary PCI were pretreated with 600 mg of clopidogrel and then randomly assigned in a double-blind manner to receive either abciximab or placebo in the intensive care unit before being sent for PCI (10). The primary end point was infarct size measured by single photon emission computed tomography before hospital discharge. At 30 days, the composite of death, recurrent myocardial infarction (MI), stroke, or urgent revascularization of the infarct-related artery was not significantly different in the 2 groups (abciximab 5%, placebo 3.8%; 95% CI 0.7 to 2.6; P=0.4). There was no significant difference in infarct size or major bleeding.

In the HORIZONS-AMI trial (9), patients undergoing primary PCI for STEMI were randomized to treatment with UFH plus a GP IIb/IIIa receptor antagonist (abciximab or double-bolus epifibatide) or to bivalirudin alone with provisional IIb/IIIa. Aspirin and a thienopyridine were adminis-
tered before catheterization. (See the full discussion of the trial under Section 4, Recommendations for the Use of Parenteral Anticoagulants.) Seven hundred fifty-seven of the 1661 patients who received UFH received a double bolus of eptifibatide and infusion, whereas 53 of 1661 in the bivalirudin arm received eptifibatide. At 30 days, rates of major bleeding and total adverse events were higher among patients treated with GP IIb/IIIa antagonists and heparin than among those given bivalirudin alone.

Two meta-analyses of randomized trials were published that compared small-molecule GP IIb/IIIa antagonists with abciximab in STEMI patients undergoing primary PCI (6,7). In each case, there was no statistically significant difference in 30-day mortality, reinfarction, or major TIMI bleeding, and there was no significant difference in death or reinfarction at 8 months between groups. There was also no statistically significant difference in postprocedural TIMI flow grade 3 or ST-segment resolution. On the basis of these studies, the present writing group judged that the totality of evidence indicates that the various GP IIb/IIIa antagonists demonstrate similar effectiveness in the setting of primary PCI.

MULTISTRATEGY was an open-label, multicenter, randomized European trial with a 2-by-2 factorial design that randomized 745 STEMI patients undergoing primary PCI to high-dose bolus tirofiban versus abciximab infusion and sirolimus-eluting stent versus bare-metal stent (BMS) (11). The prespecified primary end points were the achievement of 50% resolution of ST-segment elevation at 90 minutes after PCI, powered for noninferiority, and the rate of major adverse cardiac events (MACE) at 8 months, powered for superiority. All patients received ASA at the usual doses, clopidogrel 300 mg orally then 75 mg per day, and UFH. There was a similar rate of at least 50% ST-segment resolution at 90 minutes after primary PCI with abciximab and tirofiban (RR 1.020; 97.5% CI 0.958 to 1.086; P=0.001 for noninferiority). Rates of MACE, including all-cause death, clinical reinfarction, or TVR, and hemorrhagic (major and minor bleeding) complications were similar. The incidence of severe or moderate thrombocytopenia was more common with abciximab than with tirofiban (4.0% versus 0.8%, P=0.004).

In an analysis of the predictors of stent thrombosis after primary PCI in acute MI presented at the 2009 ACC Scientific Sessions, titled “Predictors of Stent Thrombosis After Primary Angioplasty in Acute Myocardial Infarction: The HORIZONS-AMI Trial,” (69) there was no significant difference in the 1-year rate of stent thrombosis with the heparin plus GP IIb/IIIa receptor antagonists compared with eptifibatide and abciximab (3.6% versus 2.8%, P=0.93), which suggests that eptifibatide has the same impact as abciximab on stent thrombosis incidence.

One investigation, FINESSE, addressed the issue of timing of GP IIb/IIIa antagonist administration. This double-blind, randomized, placebo-controlled study of 2453 patients with STEMI explored the use of pre-PCI treatment with a half-dose fibrinolytic agent plus abciximab, pre-PCI abciximab alone, and abciximab at the time of PCI (8). The primary end point was the composite of death due to all causes, ventricular fibrillation that occurred more than 48 hours after randomization, cardiogenic shock, and congestive heart failure during the first 90 days after randomization. The results of the trial are discussed in Section 5.1, Triage and Transfer for PCI. This trial showed no benefit (and a tendency toward excess bleeding) with prehospital abciximab compared with abciximab at the time of PCI. The writing group concluded there was no benefit of administration of abciximab before primary PCI, alone or in combination with reteplase. On the basis of this trial and ON-TIME 2, the writing group concluded that the use of GP IIb/IIIa antagonists before primary PCI is of uncertain benefit.

Given the results of the studies cited above, the writing group concluded that in the setting of dual-antiplatelet therapy with UFH or bivalirudin as the antiagulant, current evidence indicates that adjunctive use of a GP IIb/IIIa antagonist can be useful at the time of primary PCI but cannot be recommended as routine therapy. These agents might provide more benefit in selective use, for example, for the patient with a large thrombus burden or for patients who have not received adequate thienopyridine loading.

3. Recommendations for the Use of Thienopyridines

(See Table 3 and Appendix 4.)

3.1. Thienopyridines

Since the publication of the last guidelines (4,5), evidence has emerged about prasugrel, a thienopyridine that achieves greater inhibition of platelet aggregation than clopidogrel (27). The pivotal trial for prasugrel, TRITON-TIMI 38, focused on patients with ACS who were referred for PCI.

TRITON-TIMI 38 randomly assigned 13 608 patients with moderate- to high-risk ACS, 3534 of whom had STEMI, to receive prasugrel (6813 patients received a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (6795 patients received a 300-mg loading dose and a 75-mg daily maintenance dose) for an average follow-up of 14.5 months. Aspirin was prescribed within 24 hours of PCI. Clinical end points were assessed at 30 and 90 days and then every 3 to 15 months (27).

Prasugrel was associated with a significant 2.2% absolute reduction and a 19% relative reduction in the primary efficacy end point, a composite of the rate of death due to cardiovascular causes (including arrhythmia, congestive heart failure, shock, and sudden or unwitnessed death), nonfatal MI, or nonfatal stroke during the follow-up period. The primary efficacy end point occurred in 9.9% of patients receiving prasugrel and 12.1% of patients receiving clopidogrel (HR for prasugrel versus clopidogrel 0.81; 95% CI 0.73 to 0.90; P<0.001). A significant reduction in the primary end point was seen in the prasugrel group by the first prespecified time point, which was 3 days (4.7% in the prasugrel group versus 5.9% in the clopidogrel group; HR 0.73; 95% CI 0.61 to 0.87; P<0.001). Prasugrel decreased cardiovascular death, MI, and stroke by 13.8 events (NNT=46) (27). The rate of MI with subsequent death due to...
### Table 3. Recommendations for the Use of Thienopyridines

<table>
<thead>
<tr>
<th>STEMI Recommendations</th>
<th>PCI Recommendations</th>
<th>2009 Joint STEMI/PCI Focused Update Recommendations</th>
<th>Comments (All Modified Recommendations Are for Patients With ACS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2004 STEMI Guidelines, Section 7.4.4</td>
<td>2007 PCI Update, Table 14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. For patients who have undergone diagnostic cardiac catheterization and for whom PCI is planned, clopidogrel should be started and continued for at least 1 month after bare metal stent implantation and for several months after drug-eluting stent implantation (3 months for sirolimus, 6 months for paclitaxel) and for up to 12 months in patients who are not at high risk for bleeding. (Level of Evidence: B)</td>
<td>4. A loading dose of clopidogrel,* generally 600 mg, should be administered before or when PCI is performed. (Level of Evidence: C) In patients undergoing PCI within 12 to 24 hours of receiving fibrinolytic therapy, a clopidogrel oral loading dose of 300 mg may be considered. (Level of Evidence: C)</td>
<td></td>
<td>Modified recommendation (changed text).</td>
</tr>
<tr>
<td>2007 STEMI Update, Section 9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. In patients taking clopidogrel in whom CABG is planned, the drug should be withheld for at least 5 days and preferably for 7 days unless the urgency for revascularization outweighs the risks of excess bleeding. (Level of Evidence: B)</td>
<td>5. For all post-PCI stented patients receiving a DES, clopidogrel 75 mg daily should be given for at least 12 months if patients are not at high risk of bleeding. For post-PCI patients receiving a BMS, clopidogrel should be given for a minimum of 1 month and ideally up to 12 months (unless the patient is at increased risk of bleeding; then it should be given for a minimum of 2 weeks). (Level of Evidence: B)</td>
<td></td>
<td>Modified recommendation (added prasugrel).</td>
</tr>
<tr>
<td>2004 STEMI Guidelines, Section 7.4.4</td>
<td>2007 PCI Update, Table 14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. If clopidogrel is given at the time of procedure, supplementation with GP IIb/IIIa receptor antagonists can be beneficial. (Level of Evidence: B)</td>
<td>2. For patients with an absolute contraindication to aspirin, it is reasonable to give a 300-mg to 600-mg loading dose of clopidogrel, administered at least 6 hours before PCI, and/or GP IIb/IIIa antagonists, administered at the time of PCI. (Level of Evidence: C)</td>
<td></td>
<td>Deleted recommendation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Deleted recommendation</td>
</tr>
<tr>
<td>1. Continuation of clopidogrel therapy beyond 1 year may be considered in patients undergoing DES placement. (Level of Evidence: C)</td>
<td>1. Continuation of clopidogrel or prasugrel§ beyond 15 months may be considered (added prasugrel). TRITON-TIMI 38).</td>
<td></td>
<td>Modified recommendation (changed text).</td>
</tr>
</tbody>
</table>

(Continued)
cardiovascular causes was also reduced in the prasugrel group (P=0.02). The difference in the primary end point was largely related to the difference in rates of nonfatal MI (7.3% for prasugrel versus 9.5% for clopidogrel; HR 0.76; 95% CI 0.67 to 0.85; P<0.001). There were no significant differences in the 2 treatment groups in the rates of stroke or of death due to cardiovascular causes not preceded by recurrent MI (at 15 months, the nonfatal stroke rate was 1.0% for both prasugrel and clopidogrel; HR for prasugrel=1.02; CI 0.71 to 1.45; P=0.93; the rate of deaths due to cardiovascular causes not preceded by recurrent MI was 2.1% for prasugrel versus 2.4% for clopidogrel; HR 0.89; CI 0.70 to 1.12; P=0.31). There were significant reductions in the rates of ischemic events in the prasugrel group compared with the clopidogrel group: Rates of MI were 7.4% for prasugrel versus 9.7% for clopidogrel (P<0.001); urgent TVR rates were 2.5% for prasugrel versus 3.7% for clopidogrel (P<0.001); and rates of stent thrombosis were 1.1% for prasugrel versus 2.4% for clopidogrel (HR 0.48; 95% CI 0.36 to 0.64; P<0.001).

Prasugrel was associated with a significant increase in the rate of bleeding, notably, TIMI major hemorrhage, which was observed in 2.4% of patients taking prasugrel and in 1.8% of patients taking clopidogrel (HR for prasugrel versus clopidogrel 1.32; 95% CI 1.03 to 1.68, P=0.03), which represented an increase in the relative rate of major bleeding of 32%. From the standpoint of safety, prasugrel was associated with an increase of 35 TIMI major and non–coronary artery bypass graft bleeds (number needed to harm=167) (27). Also, greater rates of life-threatening bleeding were evident in the prasugrel group than in the clopidogrel group: 1.4% versus 0.9%, respectively (HR for prasugrel 1.52; 95% CI 1.08 to 2.13; P=0.01), which included nonfatal bleeding (1.1% versus 0.9%; HR for prasugrel 1.25; 95% CI 0.87 to 1.81; P=0.23) and fatal bleeding (0.4% versus 0.1%; HR for prasugrel 4.19; 95% CI 1.58 to 11.11; P=0.002). In the few patients who underwent coronary artery bypass graft (CABG), TIMI major bleeding through 15 months was also greater with prasugrel than with clopidogrel (13.4% versus 3.2%, respectively; HR for prasugrel 4.73; 95% CI 1.90 to 11.82; P<0.001) (27). Despite the increase in bleeding, the net clinical-benefit end point, which included all-cause mortality, ischemic events, and major bleeding events, favored prasugrel (27).

Prasugrel showed superior efficacy in major prespecified subgroups in the overall ACS population. The benefit tended to be greater among the 3146 patients with diabetes (12.2% of whom had the primary end point in the prasugrel group versus 17.0% in the clopidogrel group; HR 0.70; 95% CI 0.58 to 0.85; P<0.001) than among the 10 462 patients without diabetes (9.2% of whom had the primary end point in the prasugrel group versus 10.6% in the clopidogrel group; HR 0.86; 95% CI 0.76 to 0.98; P=0.02). The rate of definite or probable stent thrombosis was significantly reduced in the prasugrel group compared with the clopidogrel group, as noted (27).

A post hoc analysis suggested there were 3 subgroups of ACS patients who did not have a favorable net clinical benefit (defined as the rate of death due to any cause, nonfatal MI, nonfatal stroke, or non–CABG-related nonfatal TIMI major bleeding) from the use of prasugrel or who had net harm: Patients with a history of stroke or transient ischemic attack (TIA) before enrollment had net harm from prasugrel (HR 1.54; 95% CI 1.02 to 2.32; P=0.04), patients 75 years of age and older had no net benefit from prasugrel (HR 0.99; 95% CI 0.81 to 1.21; P=0.92); and patients with a body weight of less

---

**Table 3. Continued**

<table>
<thead>
<tr>
<th>STEMI Recommendations</th>
<th>PCI Recommendations</th>
<th>2009 Joint STEMI/PCI Focused Update Recommendations</th>
<th>Comments (All Modified Recommendations Are for Patients With ACS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class III</td>
<td></td>
<td></td>
<td>New recommendation</td>
</tr>
<tr>
<td>1. In STEMI patients with a prior history of stroke and transient ischemic attack for whom primary PCI is planned, prasugrel is not recommended as part of a dual-antiplatelet therapy regimen. (Level of Evidence: C)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*A available data for prasugrel use are for PCI for acute coronary syndrome (ACS) and not elective PCI. Recommendations for elective PCI with clopidogrel use are not being updated in this guideline focused update.*

†The optimum loading dose of clopidogrel has not been established. Randomized trials establishing its efficacy and providing data on bleeding risks used a loading dose of 300 mg orally followed by a daily oral dose of 75 mg (26,27). Higher oral loading doses such as 600 mg or more than 900 mg (36) of clopidogrel more rapidly inhibit platelet aggregation and achieve a higher absolute level of inhibition of platelet aggregation, but the additive clinical efficacy and safety of higher oral loading doses have not been rigorously established. The necessity for giving a loading dose of clopidogrel before PCI is driven by the pharmacokinetics of clopidogrel, for which several hours are required to achieve desired levels of platelet inhibition. For post-PCI patients receiving a stent (BMS or DES), a daily maintenance dose should be given for at least 12 months and for up to 15 months unless the risk of bleeding outweighs the anticipated net benefit afforded by a thienopyridine.

‡Clopidogrel loading dose after fibrinolytic therapy: For patients given fibrin- and non–fibrin-specific fibrinolytic drugs who are undergoing PCI after more than 24 hours, 300 mg; for patients given a fibrin-specific fibrinolytic undergoing PCI after more than 24 hours, 300 to 600 mg; for patients given a non–fibrin-specific fibrinolytic undergoing PCI between 24 and 48 hours, 300 mg; for patients given a non–fibrin-specific fibrinolytic undergoing PCI after 48 hours, 300 to 600 mg.

§Patients weighing <60 kg have increased exposure to the active metabolite of prasugrel and an increased risk of bleeding on a 10-mg once-daily maintenance dose. Consideration should be given to lowering the maintenance dose to 5 mg in patients who weigh <60 kg. The effectiveness and safety of the 5-mg dose have not been studied prospectively. For post-PCI patients receiving a stent (BMS or DES), a daily maintenance dose should be given for at least 12 months and for up to 15 months unless the risk of bleeding outweighs the anticipated net benefit afforded by a thienopyridine. Do not use prasugrel in patients with active pathologic bleeding or a history of transient ischemic attack or stroke. In patients >75 years of age, prasugrel is generally not recommended because of the increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk situations (patients with diabetes or a history of prior MI) in which its effect appears to be greater and its use may be considered. Do not start prasugrel in patients likely to undergo urgent CABG. When possible, discontinue prasugrel at least 7 days before any surgery. Additional risk factors for bleeding include body weight <60 kg, propensity to bleed, and concomitant use of medications that increase the risk of bleeding (e.g., warfarin, heparin, fibrinolytic therapy, or chronic use of nonsteroidal anti-inflammatory drugs).
than 60 kg had no net benefit from prasugrel (HR 1.03; 95% CI 0.69 to 1.53; P = 0.89). In both treatment groups, patients with at least 1 of these risk factors had higher rates of bleeding than those without them (27). A pharmacokinetic analysis showed greater exposure to the active metabolite of prasugrel for patients who weighed less than 60 kg and who were 75 years old or older (38).

The US Food and Drug Administration (FDA) approved prasugrel in July 2009 and incorporated the aforementioned subgroup findings into its labeling by citing a contraindication against prasugrel use in patients with a history of TIA or stroke and active pathological bleeding. The FDA further recommends that consideration be given to lowering the maintenance dose of prasugrel to 5 mg in patients who weigh less than 60 kg, with a note that the effectiveness and safety of the 5-mg dose have not been studied prospectively to date. The FDA labeling information includes a general warning against the use of prasugrel in patients older than 75 years of age because of concerns of an increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk situations (patients with diabetes or a history of prior MI), in which case its effect appears to be greater and its use may be considered (37).

In focusing specifically on patients with STEMI, the primary composite end point of cardiovascular death, nonfatal MI, or nonfatal stroke was significantly reduced in patients assigned to prasugrel at 30 days compared with patients who received clopidogrel (6.5% versus 9.5%; HR 0.68; 95% CI 0.54 to 0.87; P = 0.0017), and this trend persisted to 15 months (HR 0.79; 95% CI 0.65 to 0.97; P = 0.0221) (13). Furthermore, in the STEMI group, the key secondary end point of cardiovascular death, MI, or urgent TVR was significantly reduced with prasugrel at 30 days (P = 0.0205) and 15 months (P = 0.0250) (13). At 30 days and 15 months, the individual end points of cardiovascular death and MI, as well as stent thrombosis, were reduced with prasugrel (13).

The interaction testing for efficacy and safety showed no significant difference in bleeding risk regardless of the type of ACS (e.g., UA/NSTEMI versus STEMI). Thus, the STEMI results for efficacy and safety are consistent with the main results of the trial. In a post hoc analysis of patients with anterior MI, event rates at 15 months for the primary end point were lower with prasugrel (9.8% for prasugrel versus 16.3% for clopidogrel; HR 0.57; 95% CI 0.42 to 0.78; P = 0.0003). In patients with nonanterior MI, treatment effects did not differ for the primary end point (10.1% for prasugrel versus 9.9% for clopidogrel; HR 1.02; 95% CI 0.78 to 1.34; P = 0.8749). The test for heterogeneity of the effect of prasugrel was significant (P = 0.0053), which suggests that the benefit might vary by the location of the MI. Data were consistent in both the primary and secondary PCI subgroups (13).

The writing group weighed the current data regarding the use of thienopyridine therapy in patients who remain hospitalized after STEMI and are candidates for CABG and retained the 2007 focused update recommendation of empiric discontinuation of clopidogrel therapy for at least 5 days and at least 7 days in patients receiving prasugrel before planned CABG (2,27,30).

Platelet function testing to determine the degree of platelet inhibition (39) may be used, and if platelet function has normalized, CABG may be performed at an earlier time. Additionally, other strategies of platelet inhibition (GP IIb/IIIa receptor antagonists) may be used if recurrent ischemia is a concern during the waiting period for CABG. Ultimately, the patient’s clinical status will determine the risk-to-benefit ratio of CABG compared with awaiting restoration of platelet function.

The results of TRITON-TIMI 38 influenced dosing recommendations for loading and chronic thienopyridine therapy with prasugrel. Sixty milligrams of prasugrel is now recommended as a loading dose for primary PCI in STEMI. For secondary PCI in those patients who have recurrent ischemia or other reasons for planned intervention during their course of treatment, 60 mg of prasugrel may be given after the coronary anatomy has been identified (to avoid dosing those patients who require CABG) either before, during, or within 1 hour of PCI (27). Furthermore, 10 mg of prasugrel may be used in addition to ASA for chronic dual-antiplatelet therapy (27).

Determination of patient groups that should be considered for continuation of dual-antiplatelet treatment beyond 12 months is based on patient-level factors (e.g., age, history of bleeding) and lesion characteristics (e.g., bifurcation, small-diameter vessel) (28).

In previous studies of patients with prior stroke or TIA, use of dual-antiplatelet therapy has been associated with an increased risk of adverse outcomes, notably intracranial bleeding, compared with single-antiplatelet therapy. In the MATCH (Management of Atherothrombosis With Clopidogrel in High-Risk Patients With TIA or Stroke) trial (40) in which patients with prior stroke or TIA and additional risk factors (n = 7599) were allocated to clopidogrel 75 mg or combination therapy with clopidogrel 75 mg plus ASA 75 mg per day, there was no significant benefit of combination therapy compared with clopidogrel alone in reducing the primary outcome of the composite of ischemic stroke, MI, vascular death, or rehospitalization due to ischemic events, or any of the secondary outcomes. The risk of major hemorrhage was significantly increased in the combination-therapy group compared with those given clopidogrel alone, with a 1.3% absolute increase in life-threatening bleeding. Although clopidogrel plus ASA is recommended over ASA alone for patients with ACS (41–43), the results of MATCH do not suggest a similar risk-benefit ratio for stroke and TIA survivors. The AHA/American Stroke Association’s Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Stroke contain a Class III recommendation for the use of ASA in combination with clopidogrel in patients with prior stroke or TIA (44). On the other hand, a post hoc analysis from the CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) trial, which included 9478 patients, suggested that patients with documented prior MI, ischemic stroke, or symptomatic peripheral artery disease derive benefit from dual-antiplatelet therapy with clopidogrel plus ASA (45). Although MATCH and CHARISMA did not involve STEMI patients, the writing group recommended weighing the benefits and risks of
prescribing clopidogrel and ASA in patients with a recent history of TIA or stroke. Given prasugrel’s greater tendency to cause intensive inhibition of platelet aggregation in general and the findings of increased levels of bleeding compared with clopidogrel in this population, the use of prasugrel as part of a dual-antiplatelet therapy regimen in patients with prior stroke or TIA is contraindicated (37).

3.1.1. Additional Thiopyridine Information
Although clopidogrel in combination with ASA has been shown to reduce recurrent coronary events in the posthospitalized ACS population (32,43,46), the response to clopidogrel varies among patients, and clopidogrel resistance has been observed (43). Information is accumulating about the variations in the antiplatelet effect of clopidogrel in patients with loss-of-function alleles in the gene encoding CYP450 2C19 (32,46–50). These patients form a subgroup in which failure of clopidogrel effectiveness has been linked to adverse clinical outcomes (30,47–51). In TRITON-TIMI 38 and 3 of the cohort studies (47,49,52), patients who were carriers of a reduced-function CYP450 2C19 allele had significantly lower levels of the active metabolite of clopidogrel, diminished platelet inhibition, and increased rates of cardiovascular events (e.g., death, MI, stroke), including stent thrombosis (53), compared with the extensive metabolizers (54). In another cohort study with 2208 patients (50), the increased event rate was observed only in poor metabolizers. (Prasugrel has a higher level of inhibition of platelet aggregation than clopidogrel and a more rapid onset of action [55]. Its metabolism is not affected by the 2C19 allele variant [56].)

Accordingly, the effective clopidogrel dose for an individual undergoing PCI for STEMI may not be known. A large randomized trial (57) is attempting to determine whether adjustment of clopidogrel therapy on the basis of platelet function testing with a point-of-care assay safely improves outcomes after PCI with DES. As noted in the drug dosing table (Appendix 4), the current recommended loading dose for clopidogrel is uncertain. In addition, a period of several hours is required to metabolize clopidogrel to its active metabolite, which leaves a window of time during which there is a reduced level of effectiveness even in responders.

With regard to clopidogrel loading for PCI after a patient has received fibrinolytic therapy, there are no studies that have formally tested a 600-mg (or higher) clopidogrel loading dose administered with fibrinolytic treatment. The only study that tested any clopidogrel dose with a fibrinolytic was the CLARITY-TIMI 28 (Clopidogrel as Adjunctive Reperfusion Therapy–Thrombolysis in Myocardial Infarction 28) study, which randomized 3491 patients 75 years of age and younger who were receiving fibrinolytic therapy within 12 hours of STEMI to clopidogrel (300-mg oral loading dose; 75-mg oral daily maintenance dose) or placebo (58). As described in the 2007 STEMI focused update (4), patients who received clopidogrel had a reduced rate of an occluded infarct artery, accomplished by preventing infarct-related reoclusion rather than by facilitating early reperfusion.

When considering a loading dose of clopidogrel for PCI after a patient has received a fibrinolytic agent, the available level of evidence is limited (Level of Evidence: C), and consensus opinion suggests it is dependent on how many hours have elapsed since fibrinolytic therapy was administered before PCI. For patients who have received any fibrinolytic agent and subsequently proceed to PCI within 24 hours, a dose of 300 mg of clopidogrel as a loading dose is suggested. If the patient received a fibrin-specific fibrinolytic agent and then proceeds to PCI after 24 hours has elapsed, a loading dose of 300 to 600 mg may be considered. If at least 48 hours has elapsed after treatment with a non–fibrin-specific fibrinolytic agent, a dose of 300 to 600 mg may be considered.

Prasugrel has not been studied in patients who have received fibrinolytic therapy. Thus, for STEMI patients undergoing nonprimary PCI who received prior fibrinolytic therapy without a thienopyridine, only a loading dose with clopidogrel should be given as the thienopyridine of choice.

3.1.2. Choice of Thiopyridine for PCI in STEMI
The guidelines do not endorse explicitly one of the thienopyridines over the other. There were several reasons for this decision. Although the composite efficacy end point favored prasugrel, driven predominantly by a difference in nonfatal MIs, with deaths and nonfatal strokes being similar, bleeding was increased in the prasugrel group (27). In addition, the comparison of the 2 drugs is based on a single large trial. Also, the loading dose of clopidogrel in TRITON-TIMI 38 was lower than is currently recommended in these guidelines. Furthermore, there are some emerging studies that suggest there may be some patients who are resistant to clopidogrel, but there is little information about the use of strategies to select patients who might do better with prasugrel. There is not yet experience with the use of prasugrel in routine community practice. As a result, the writing group believes that there is some uncertainty regarding the net benefit and risks of 1 drug over another for a given patient. Considerations of efficacy in the prevention of thrombosis and risk of an adverse effect related to bleeding, as well as experience with a given medication, may best guide decisions about the choice of thienopyridine for individual patients.

3.2. Proton Pump Inhibitors and Dual-Antiplatelet Therapy for ACS
Proton pump inhibitors (PPIs) are often prescribed prophylactically when clopidogrel is started, to prevent gastrointestinal complications such as ulceration and related bleeding (59) due to dual-antiplatelet therapy, in particular ASA and clopidogrel (32). Coupled with concern about the gastrointestinal precautions, there has been increased emphasis on the prevention of premature discontinuation of dual-antiplatelet therapy, particularly in patients who have received a stent (BMS or DES), for whom 12 months of antiplatelet therapy is recommended (28). PPI medications* have been found to interfere with the metabolism of clopidogrel (34).

Although there are studies that show a pharmacodynamic interaction on ex vivo platelet function testing, to date there are no convincing randomized clinical trial data for an important clinical drug–drug interaction. Retrospective claims-based re-

*PPIs include omeprazole, lansoprazole, pantoprazole, rabeprazole, and esomeprazole (which are all available by prescription). Omeprazole is also sold over the counter for frequent heartburn (66).
ports suggesting clinical harm, some detailed below, may be confounded by different baseline characteristics and lack of compliance data. There have been retrospective reports of adverse cardiovascular outcomes (e.g., readmission for ACS) when the antiplatelet regimen of clopidogrel and ASA is accompanied by PPIs, assessed as a group, compared with the use of this regimen without a PPI (32–34,60). In a retrospective cohort study from the Veterans Affairs’ medical records and pharmacy database, concomitant clopidogrel and PPI therapy (with omeprazole, rabeprazole, lansoprazole, or pantoprazole) at any time point during follow-up of 8205 patients discharged for ACS was associated with an increased risk of death or rehospitalization for ACS (32). Other post hoc study analyses (50,61) and a retrospective data analysis from the NHLBI Dynamic Registry (62) in which PPIs were assessed as a class in combination with a clopidogrel and an ASA regimen have not found an effect of PPI therapy on the clinical effect of clopidogrel in ACS patients, after ACS, or in a general post-PCI population, respectively (50,61,62).

Some studies have suggested that adverse cardiovascular outcomes with the combination of clopidogrel and a PPI are explained by the individual PPI, in particular the use of a PPI that inhibits CYP450 2C19, which includes omeprazole, lansoprazole, and rabeprazole. The PPI omeprazole notably has been reported to significantly decrease the inhibitory effect of clopidogrel on platelet aggregation (63,64). One study reported that the PPI pantoprazole was not associated with recurrent MI among patients receiving clopidogrel, possibly because of its lack of inhibition of CYP450 2C19 (33).

Other studies have examined the thienopyridine agent prescribed with the PPI. One open-label drug study evaluated the effects of the PPI lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects given single doses of prasugrel (60 mg) and clopidogrel (300 mg) with and without concurrent lansoprazole 30 mg per day. The data suggest that inhibition of platelet aggregation was reduced in patients who took the combination of clopidogrel and lansoprazole, whereas it was unaffected after a prasugrel dose (56).

Another study (35) assessed the association of PPIs with the pharmacodynamics and clinical efficacy of clopidogrel and prasugrel, based on populations from 2 randomized trials, the PRINCIPLE (Prasugrel In Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation) TIMI-44 trial (65) and the TRITON-TIMI 38 trial (27). The findings indicated that first, PPI treatment attenuated the pharmacodynamic effects of clopidogrel and, to a lesser extent, those of prasugrel. Secondly, PPI treatment did not affect the clinical outcome of patients given clopidogrel or prasugrel. This finding was true for all PPIs that were studied, including omeprazole and pantoprazole.

The FDA communication concerning an ongoing safety review of clopidogrel bisulfate (66) advises that healthcare providers avoid the use of clopidogrel in patients with impaired CYP2C19 function due to known genetic variation or due to drugs that inhibit CYP2C19 activity. The FDA notes there is no evidence that other drugs that reduce stomach acid, such as H2 blockers or antacids, interfere with the antiplatelet activity of clopidogrel.

Further research with thienopyridines and PPI combinations, particularly drugs that are not dependent on CYP450 2C19, is needed. Consideration may be given to the use of H2 antagonists as an alternative to PPIs in the setting of dual antiplatelet therapy, although they cannot be relied on to protect as well as PPIs, and there are few data about their use with ASA (59). The FAMOUS (Famotidine for the Prevention of Peptic Ulcers in Users of Low-Dose Aspirin) trial, a phase II, double-blind, randomized, placebo-controlled trial, found that among patients with a history of coronary heart disease, diabetes mellitus, or cerebrovascular disease who were taking low-dose ASA, 12 weeks of famotidine 20 mg twice daily (n = 204) compared with placebo twice daily (n = 200) was beneficial in reducing the incidence of peptic ulcer or esophagitis during follow-up endoscopy at 12 weeks. The rate of occurrence of a gastric ulcer at endoscopy at 12 weeks was 3.4% in the famotidine group versus 15% in the placebo group (P = 0.0002), duodenal ulcer occurred in 0.5% versus 8.5% (P = 0.0045), and erosive esophagitis was seen in 4.4% versus 19% (P < 0.0001), respectively. Of note, in the famotidine group, clopidogrel use was 19% and dipyridamole use was 6% (67). The writing committee concluded that additional data, notably randomized controlled clinical trial data that have been peer reviewed and published, are needed before an official recommendation can be made about the use of dual antiplatelet therapy with PPIs in the setting of ACS.

4. Recommendations for the Use of Parenteral Anticoagulants

(See Table 4 and Appendix 4.)

4.1. Parenteral Anticoagulants

Parenteral anticoagulants include intravenous UFH, bivalirudin, enoxaparin, and fondaparinux. Bivalirudin was briefly cited in the 2007 STEMI focused update. The HORIZON-AMI trial, which was reported subsequently, was a prospective, open-label, randomized, multicenter, international trial that included 3602 patients with STEMI undergoing primary PCI. Patients were randomized to treatment with UFH plus a GP IIb/IIIa receptor antagonist or to bivalirudin alone (with provisional abciximab or double-bolus epifibatide). The primary efficacy end point was a composite of net adverse clinical events, including major bleeding plus MACE, a composite of cardiovascular death, reinfarction, TVR for ischemia, and stroke within 30 days. Bivalirudin alone resulted in a lower incidence of net adverse clinical events at 30 days (9.2% versus 12.1%; RR 0.76; 95% CI 0.63 to 0.92; P = 0.005; NNT = 34) and at 1 year (15.7% versus 18.3%, HR 0.84; 95% CI 0.71 to 0.98; P = 0.3) (9). The difference was driven by a significant decrease in major bleeding complications with bivalirudin at 30 days (4.9% versus 8.3%, P = 0.001; number needed to harm 33) and 1 year (5.8% versus 9.2%, P = 0.001). There was a statistically significant 1% increase in stent thrombosis (n = 17) within the first 24 hours with bivalirudin but no subsequent difference (1.3% versus 0.3%, P < 0.001). More deaths at 30 days occurred after major bleeding (n = 26) than after reinfarction (n = 10) or definite stent thrombosis (n = 5) (9). Treatment with bivalirudin resulted in significantly lower 30-day rates of death due to
cardiac causes (1.8% versus 2.9%; RR 0.62; 95% CI 0.40 to 0.95; \( P=0.03 \)) and death due to all causes (2.1% versus 3.1%; RR 0.66; 95% CI 0.44 to 1.00; \( P=0.047 \) compared with UFH plus GP IIb/IIIa inhibitors). At 1 year, MACE rates were identical, but there was a decrease in all-cause mortality with bivalirudin (3.4% versus 4.8%, \( P=0.03 \)) (68).

Concerns about the trial include its open-label design and the administration of UFH before randomization in 66% of patients in the bivalirudin arm and 76% of patients in the UFH plus GP IIb/IIIa inhibitors arm. Only 615 patients received bivalirudin monotherapy, and only 60% of patients in the trial received a 600-mg clopidogrel loading dose. Major bleeding as defined in the publication included hematomas of 5 cm, intracranial hemorrhage, and bleeding that required surgery. Additionally, the study put forth a composite primary end point that combined efficacy and safety. Although there were no statistically significant interactions at 30 days between the treatment assignment and preprocedural UFH use or clopidogrel loading dose with respect to MACE or major bleeding, the occurrence of an increase in early stent thrombosis with bivalirudin and the excess bleeding with UFH and GP IIb/IIIa inhibitors may be related to the degree of platelet inhibition and antithrombin activity associated with these treatment doses.

A preliminary report suggested that the use of bivalirudin alone (\( P=0.005 \)) and a lower loading dose of clopidogrel (300 versus 600 mg; \( P=0.01 \)) were independent predictors of acute and subacute stent thrombosis rates, respectively (69). Probability values for secondary end points may not have been adjusted for multiple looks.

Therefore, the writing group now considers bivalirudin useful for primary PCI in STEMI whether or not the patient received pretreatment with UFH. The risk of acute stent thrombosis associated with bivalirudin appeared to be mitigated by the prior use of UFH and the risk of subacute stent thrombosis by the use of a 600-mg loading dose of clopidogrel. These data should be confirmed by prospective studies.

### 5. Recommendations for Triage and Transfer for PCI

(See Table 5 and Appendix 5.)

#### 5.1. Triage and Transfer for PCI

**5.1.1. STEMI Patients Who Are Candidates for Reperfusion**

The 2007 STEMI Focused Update describes several strategies for reperfusion, among them facilitated PCI and rescue PCI (4). These terms are no longer used for the recommen-
### Table 5. Recommendations for Triage and Transfer for PCI

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Class I</strong></td>
<td></td>
<td>New recommendation</td>
</tr>
</tbody>
</table>
| 1. Each community should develop a STEMI system of care that follows standards at least as stringent as those developed for the AHA’s national initiative, Mission: Lifeline, to include the following:  
  - ongoing multidisciplinary team meetings that include emergency medical services, non–PCI-capable hospitals/STEMI referral centers, and PCI-capable hospitals/STEMI receiving centers to evaluate outcomes and quality improvement data;  
  - a process for prehospital identification and activation;  
  - destination protocols for STEMI receiving centers;  
  - transfer protocols for patients who arrive at STEMI referral centers who are primary PCI candidates, are ineligible for fibrinolytic drugs, and/or are in cardiogenic shock. | (Level of Evidence: C) | |

**Class IIa**

1. It is reasonable for high-risk* patients who receive fibrinolytic therapy as primary reperfusion therapy at a non–PCI-capable facility to be transferred as soon as possible to a PCI-capable facility where PCI can be performed either when needed or as a pharmacoinvasive strategy. Consideration should be given to initiating a preparatory antithrombotic (anticoagulant plus antiplatelet) regimen before and during patient transfer to the catheterization laboratory. (Level of Evidence: B) | New recommendation (see Appendix 5) | |

**Class IIb**

1. Patients who are not at high risk who receive fibrinolytic therapy as primary reperfusion therapy at a non–PCI-capable facility may be considered for transfer as soon as possible to a PCI-capable facility where PCI can be performed either when needed or as a pharmacoinvasive strategy. Consideration should be given to initiating a preparatory antithrombotic (anticoagulant plus antiplatelet) regimen before and during patient transfer to the catheterization laboratory. | (Level of Evidence: C) | Modified recommendation (changed text).  
Deleted recommendation (covered by new recommendations, above) |

*High risk was defined in the CARESS-in-AMI (15) study as STEMI patients with ≥1 high-risk feature (extensive ST-segment elevation, new-onset left bundle-branch block, previous MI, Killip class ≥2, or left ventricular ejection fraction ≤35% for inferior MIs; anterior MI alone with ≥2 mm of ST elevation in ≥2 leads also qualified the patient as being at high risk). It was defined in TRANSFER-AMI (14) as ≥2 mm of ST-segment elevation in 2 anterior leads or ST elevation of at least 1 mm in inferior leads with at least 1 of the following: systolic blood pressure <100 mm Hg, heart rate >100 bpm, Killip class II to III, ≥2 mm of ST-segment depression in the anterior leads, or ≥1 mm of ST elevation in right-sided lead V1, indicative of right ventricular involvement.

A brief review of facilitated PCI, however, is needed. This strategy involves full- or half-dose fibrinolytic therapy with or without a GP IIb/IIIa receptor antagonist, followed by immediate PCI. Two studies addressed this issue: ASSENT-4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy With Percutaneous Coronary Intervention) (70), which was described in detail in the 2007 PCI and STEMI focused updates, and FINESSE (71), which was a randomized, double-blind clinical trial of 2452 patients randomized within 6 hours of symptom onset to receive reduced-dose reteplase plus abciximab followed by PCI (combination-facilitated PCI), abciximab alone followed by PCI (abciximab-facilitated PCI), or placebo (primary PCI).

ASSENT-4 patients treated with fibrinolytic therapy before PCI had increased rates of adverse outcomes, including in-hospital death (6% versus 3%). The investigators theorized that suboptimal antithrombotic therapy (i.e., the lack of a heparin infusion after bolus administration, no upfront loading dose of clopidogrel, and prohibition of IIb/IIIa use except for bailout) and a short time from fibrinolytic therapy to PCI contributed in part to the adverse clinical outcomes.
FINESSE (8) showed that neither PCI preceded by abciximab and reteplase nor PCI preceded by abciximab alone was superior to abciximab used at the time of PCI among patients presenting within 4 hours of medical contact. Neither the primary end point (a composite of death due to all causes, ventricular function more than 48 hours after randomization, cardiogenic shock, and congestive heart failure during the first 90 days after randomization) nor mortality was significantly different among the groups. Although the study was terminated early because of recruitment challenges, there was less than a 2% chance that the primary treatment group difference would be significant if the trial had been allowed to continue to its planned completion.

The indications for rescue PCI have been defined by a combination of clinical and electrocardiographic clues that an infarct artery has not reperfused. These are relief of pain and resolution of ST-segment elevation. Although complete relief of pain and complete resolution of ST elevation are reasonably predictive of reperfusion after fibrinolytic therapy, this is not a common occurrence. In the 2007 STEMI Focused Update, the writing committee held that at 90 minutes after initiation of fibrinolytic therapy, if there was less than 50% ST-segment resolution in the lead that showed the greatest degree of ST elevation at presentation, then fibrinolytic therapy had likely failed to reperfuse the patient (4). If the judgment was made that fibrinolytic therapy had not resulted in reperfusion after 90 minutes, then PCI performed at that time was labeled rescue PCI.

The 2007 STEMI Focused Update (4) recommended rescue PCI in the following cases: Fibrinolytic-treated STEMI patients meeting high-risk criteria (i.e., cardiogenic shock [less than 75 years of age, Class I; 75 years of age or older, Class IIa]); hemodynamic or electrical instability; persistent ischemic symptoms; and for certain moderate- and high-risk patients who did not strictly meet the above criteria (Class IIb). These recommendations were based on results of the REACT (Rescue Angioplasty Versus Conservative Treatment of Repeat Thrombolysis) trial (74) which showed a clear benefit of rescue PCI (over repeated doses of fibrinolytics or medical management) in moderate- to high-risk patients with failed reperfusion, as well as a meta-analysis of 8 rescue PCI trials (including REACT) (73–76). The 2007 focused update acknowledged that the expected benefits of rescue PCI are greater the earlier it is initiated after the onset of ischemic symptoms.

Two new trials have helped inform this update: The CARESS-in-AMI trial and the TRANSFER-AMI trial. CARESS-in-AMI (15) studied 600 STEMI patients 75 years of age or younger with at least 1 high-risk feature (extensive ST-segment elevation, new-onset left bundle-branch block, previous MI, Killip class greater than 2, or left ventricular ejection fraction 35% or less) who were treated initially at non-PCI hospitals with half-dose reteplase, abciximab, heparin, and ASA within 12 hours of symptom onset (3). All patients were randomized to immediate transfer for PCI or to standard treatment with transfer for rescue PCI if needed. PCI was performed in 85.6% of patients in the immediate PCI group, and rescue PCI was performed in 30.3% of the standard treatment/transfer for rescue PCI group. There was a shorter median time from fibrinolytic therapy to transfer to a PCI-capable center in the immediate versus the rescue PCI group (110 versus 180 minutes, \( P < 0.0001 \)). Antiplatelet therapy with ASA and clopidogrel was used less frequently in the standard care/rescue arm than in the early intervention group. The primary outcome (composite of all-cause mortality, reinfarction, and refractory myocardial ischemia within 30 days of randomization) occurred significantly less often (4.4% versus 10.7%, \( P = 0.004 \)) in the immediate PCI group than in the standard care/rescue PCI group (NNT = 17). There were no significant differences in the rates of major bleeding at 30 days (3.4% versus 2.3%, \( P = 0.47 \)) or stroke (0.7% versus 1.3%, \( P = 0.50 \)) between groups. These results suggest that high-risk STEMI patients treated at non-PCI hospitals with a preparatory pharmacological strategy of half-dose fibrinolytic therapy, abciximab, heparin, and ASA have improved outcomes when transferred immediately to a PCI facility rather than when medical therapy is continued with transfer for rescue PCI only if there is evidence of failed reperfusion.

The TRANSFER-AMI study (14) further tested the pharmacoinvasive strategy concept in high-risk STEMI patients. Accordingly, 1059 patients who presented to a non-PCI-capable hospital within 12 hours of symptom onset of STEMI who had at least 1 high-risk feature (greater than or equal to 2 mm of ST-segment elevation in 2 anterior leads, systolic blood pressure less than 100 mm Hg, heart rate higher than 100 bpm, Killip class II to III, 2 mm or more of ST-segment depression in the anterior leads, or 1 mm or more of ST elevation in right-sided lead V4 indicative of right ventricular involvement for inferior MIs; anterior MI alone with 2 mm or more of ST-segment elevation in 2 or more leads also qualified) and who were treated with fibrinolytic therapy were randomized to a pharmacoinvasive strategy (immediate transfer for PCI within 6 hours of fibrinolytic therapy) or to standard treatment after fibrinolytic therapy, which included rescue PCI as required for ongoing chest pain and less than 50% resolution of ST elevation at 60 to 90 minutes or hemodynamic instability. Standard-treatment patients who did not require rescue PCI remained at the initial hospital for at least 24 hours, and coronary angiography within the first 2 weeks was encouraged.

All patients received standard-dose tenecteplase, ASA, and either UFH or enoxaparin. Clopidogrel loading (300 mg for patients 75 years of age or younger and 75 mg for those older than 75 years of age) was strongly encouraged in all study patients. GP IIb/IIIa receptor antagonists were administered at the PCI-capable hospitals according to standard practice at the institution. The primary end point of the trial was the 30-day composite of the first occurrence of death, reinfarction, recurrent ischemia, new or worsening heart failure, and cardiogenic shock.

The median time to administration of tenecteplase from onset of symptoms was approximately 2 hours in both groups, whereas the median time from tenecteplase administration to catheterization was 2.8 hours in the pharmacoinvasive group and 3.25 hours in the standard-treatment group. Coronary angiography was performed in 98.5% versus 88.7% and PCI.
The primary end point of the trial occurred in 11.0% of the pharmacoinvasive group compared with 17.2% of the standard-treatment group (RR 0.64; 95% CI 0.47 to 0.84; P = 0.004). Importantly, the incidence of TIMI major and minor bleeding and GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) (77) moderate and severe bleeding was not different between groups, although there was a higher incidence of GUSTO mild bleeding in the pharmacoinvasive group (13.0% compared with 9.0% in the standard-treatment group, P = 0.036). The authors concluded that after treatment with fibrinolytic therapy in STEMI patients presenting to hospitals without PCI capability, transfer to a PCI center to undergo coronary angiography and PCI should be initiated immediately without waiting to determine whether reperfusion has occurred. These results lend further support to the routine, early transfer of high-risk, fibrinolytic-treated patients to a PCI center for early PCI supported by contemporary antithrombotic therapy.

On the basis of this evidence, a pathway has been suggested for the care of STEMI patients that has been divided into those patients presenting to a PCI-capable facility and those presenting to a non–PCI-capable facility (Appendix 5). Those seen at a PCI-capable facility should be moved expeditiously to the catheterization laboratory, with appropriate antithrombotic therapy for catheterization and PCI if appropriate. There has been discussion about whether the recommended door-to-balloon time (or first medical contact–to-balloon time) should be greater than 90 minutes, with the recognition that in certain patients, the mortality advantage of primary PCI compared with fibrinolytic therapy is maintained with more prolonged door-to-balloon times (78). However, the writing groups continue to believe that the focus should be on developing systems of care to increase the number of patients with timely access to primary PCI rather than extending the acceptable window for door-to-balloon time (79). Moreover, in a study of 43 801 patients with STEMI undergoing primary PCI within the National Cardiovascular Data Registry, any delay in time to reperfusion after arrival at the hospital was associated with a higher adjusted risk of in-hospital mortality in a continuous, nonlinear fashion (30 minutes = 3.0%, 60 minutes = 3.5%, 90 minutes = 4.3%, 120 minutes = 5.6%, 150 minutes = 7.0%, and 180 minutes = 8.4%; P < 0.001) (80). Rather than accepting a 90-minute door-to-balloon benchmark for primary PCI, these data suggest an as-soon-as-possible standard.

Those patients presenting to a non–PCI-capable facility should be triaged to fibrinolytic therapy or immediate transfer for PCI. This decision will depend on multiple clinical observations that allow judgment of the mortality risk of the STEMI, the risk of fibrinolytic therapy, the duration of the symptoms when first seen, and the time required for transport to a PCI-capable facility (3). If primary PCI is chosen, the patient will be transferred for PCI. If fibrinolytic therapy is chosen, the patient will receive the agent(s), and a judgment as to whether the patient is high risk or not will be made. If high risk, the patient should receive appropriate antithrombotic therapy and be moved immediately to a PCI-capable facility for diagnostic catheterization and consideration of PCI. If not high risk, the patient may be moved to a PCI-capable facility after receiving antithrombotic therapy or may be observed in the initial facility.

Patients best suited for transfer for PCI are those STEMI patients who present with high-risk features, those with high bleeding risk from fibrinolytic therapy, and patients presenting late, that is, more than 4 hours after onset of symptoms. The decision to transfer is a judgment made after consideration of the time required for transport and the capabilities of the receiving hospital (2,5). Patients best suited for fibrinolytic therapy are those who present early after symptom onset with low bleeding risk. After fibrinolytic therapy, if the patient is not at high risk, transfer to a PCI-capable facility may be considered, especially if symptoms persist and failure to reperfuse is suspected.

The duration of symptoms should continue to serve as a modulating factor in selecting a reperfusion strategy for STEMI patients. Although patients at high risk (e.g., those with congestive heart failure, shock, and contraindications to fibrinolytic therapy) are best served with timely PCI, “inordinate delays between the time from symptom onset and effective reperfusion with PCI may prove deleterious, especially among the majority of STEMI patients at relatively low risk” (p 1299) (81). Accordingly, each community and each facility in that community should have an agreed-upon plan for how STEMI patients are to be treated. This includes which hospitals should receive STEMI patients from emergency medical services units capable of obtaining diagnostic ECGs, management at the initial receiving hospital, and written criteria and agreements for expeditious transfer of patients from non–PCI-capable to PCI-capable facilities (82).

The development of regional systems of STEMI care is a matter of utmost importance (83,84). This includes encouraging the participation of key stakeholders in collaborative efforts to evaluate care using standardized performance and quality improvement measures, such as those endorsed by the ACC and the AHA for ACS (85). Standardized quality-of-care data registries designed to track and measure outcomes, complications, and adherence to evidence-based processes of care for ACS are also critical: programs such as the National Cardiovascular Data Registry ACTION Registry, the AHA’s “Get With The Guidelines” quality improvement program, and those performance-measurement systems required by the Joint Commission and the Centers for Medicare and Medicaid Services (86–89). More recently, the AHA has promoted its “Mission: Lifeline” initiative, which was developed to encourage closer cooperation and trust among prehospital emergency services, and cardiac care professionals (90). The evaluation of STEMI care delivery across traditional care-delivery boundaries with these tools and other resources is imperative to identify systems problems and to enable the application of modern quality improvement methods, such as Six Sigma, to make necessary improvements (70,91–93).

6. Recommendations for Intensive Glucose Control in STEMI

(See Table 6.) (94–96)
1. During the acute phase (first 24 to 48 hours) of management of STEMI in patients with hyperglycemia, it is reasonable to administer an insulin infusion to normalize blood glucose even in patients with an uncomplicated course. *(Level of Evidence: B)*

### 6.1. Intensive Glucose Control

As detailed in the 2004 STEMI guideline and the 2007 UA/NSTEMI guideline revision, randomized trial evidence supported the use of insulin infusion to control hyperglycemia in critically ill patients. A recently published randomized clinical trial of intensive versus conventional glucose control in critically ill patients raised uncertainty regarding the optimal level to target when achieving glucose control. NICE-SUGAR, a large, international randomized trial of adults admitted to the intensive care unit with either medical or surgical conditions, compared intensive glucose control (target glucose range 81 to 108 mg/dL) with conventional glucose control (to achieve a glucose level less than 180 mg/dL, with reduction and discontinuation of insulin if the blood glucose level dropped below 144 mg/dL) (16). Time-weighted glucose levels achieved were 115±18 mg/dL in the intensive glucose control group versus 144±23 mg/dL in the conventional glucose control group. The risk of death was increased at 90 days in the intensive glucose control group by 2.6% (27.5% versus 24.9%; odds ratio 1.14; 95% CI 1.02 to 1.08; *P*=0.02; number needed to harm=38). The result remained the same after adjustment for potential confounders. There were significantly more episodes of treatment-related hypoglycemia in the intensely managed group (6.8% versus 0.5%, *P*=0.001), although the contribution of hypoglycemia to excess mortality is uncertain (94,98). Overall, the hospital course and proximate causes of death were similar in the 2 groups. Excess deaths in the intensive-control group were predominantly due to cardiovascular causes (absolute difference 5.8%; *P*=0.02). More patients in the intensive-control group than in the conventional-control group were treated with corticosteroids.

Because NICE-SUGAR enrolled critically ill medical and surgical patients, the degree to which its results can be extrapolated to the management of patients with STEMI is unclear. Although recent data from a small, mechanistic clinical trial (28,29,98) suggest that glucose control may reduce inflammation and improve left ventricular ejection fraction in patients with acute myocardial infarction (AMI), whether it will improve patient outcomes remains uncertain.

A consensus statement by the American Association of Clinical Endocrinologists and the American Diabetes Association (99) summarized that “although hyperglycemia is associated with adverse outcomes after AMI, reduction of glycemia per se, and not necessarily the use of insulin, is associated with improved outcomes. It remains unclear, however, whether hyperglycemia is a marker of underlying health status or is a mediator of complications after AMI. Noniatrogenic hypoglycemia has also been associated with adverse outcomes and is a predictor of higher mortality” (p 1120) (99).

There is a clear need for a well-designed, definitive randomized trial of target-driven glucose control in STEMI that has meaningful clinical end points to determine glucose treatment thresholds and glucose targets. Until such a trial is completed, and based on the balance of current evidence (99–101), the writing group concluded that it was prudent to change the recommendation for the use of insulin to control blood glucose in STEMI from a Class I to a Class IIa recommendation *(Level of Evidence: B)* and to recommend treatment for hyperglycemia greater than 180 mg/dL while avoiding hypoglycemia.

### 7. Recommendation for Thrombus Aspiration During PCI for STEMI

*(See Table 7.)*

### Table 6. Recommendations for Intensive Glucose Control in STEMI

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class I</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. An insulin infusion to normalize blood glucose</td>
<td>Recommendation is no longer current.</td>
<td></td>
</tr>
<tr>
<td>is recommended for patients with STEMI and</td>
<td>See 2009 Class IIa recommendation #1.</td>
<td></td>
</tr>
<tr>
<td>complicated courses. <em>(Level of Evidence: B)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Class IIa</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. During the acute phase (first 24 to 48 hours) of</td>
<td>1. It is reasonable to use an insulin-based regimen to achieve and maintain glucose levels less than 180 mg/dL while avoiding hypoglycemia* for patients with STEMI with either a complicated or uncomplicated course (16,94–96). <em>(Level of Evidence: B)</em></td>
<td>New recommendation</td>
</tr>
<tr>
<td>the management of STEMI in patients with</td>
<td></td>
<td></td>
</tr>
<tr>
<td>hyperglycemia, it is reasonable to administer an</td>
<td></td>
<td></td>
</tr>
<tr>
<td>insulin infusion to normalize blood glucose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>even in patients with an uncomplicated course.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>(Level of Evidence: B)</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*There is uncertainty about the ideal target range for glucose necessary to achieve an optimal risk-benefit ratio.*

### Table 7. Recommendation for Thrombus Aspiration During PCI for STEMI

<table>
<thead>
<tr>
<th>2009 Joint STEMI/PCI Focused Update Recommendation</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class IIa</td>
<td></td>
</tr>
<tr>
<td>1. Aspiration thrombectomy is reasonable for</td>
<td>New recommendation</td>
</tr>
<tr>
<td>patients undergoing primary PCI (17,18,102).</td>
<td><em>(Level of Evidence: B)</em></td>
</tr>
</tbody>
</table>
Table 8. Recommendations for the Use of Stents in STEMI

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class Ila</td>
<td>1. It is reasonable to use a DES as an alternative to a BMS for primary PCI in STEMI (11,105). (Level of Evidence: B)*</td>
<td>New recommendation</td>
</tr>
<tr>
<td>Class IIB</td>
<td>1. A DES may be considered for clinical and anatomic settings in which the effectiveness/safety profile appears favorable but has not been fully confirmed by clinical trials. (Level of Evidence: C)</td>
<td>Modified recommendation (level of evidence changed from C to B).</td>
</tr>
</tbody>
</table>

*Consideration for the use of stents (DES or BMS) in STEMI should include the ability of the patient to comply with prolonged dual-antiplatelet therapy, the bleeding risk in patients undergoing chronic oral anticoagulation, and the possibility that the patient may need surgery during the ensuing year (28).

†For example, small vessels, long lesions, or diabetes mellitus. This recommendation applies to primary and nonprimary PCI patients with STEMI.

7.1. Thrombus Aspiration

Since the publication of the last STEMI and PCI focused updates, 2 new trials of manual thrombus aspiration have been published. TAPAS was a single-center, unblinded, randomized clinical trial that compared 2 catheter-based reperfusion strategies in 1071 patients with STEMI (17,102). Before coronary angiography, patients were randomized to manual thrombus aspiration before PCI (55.1% by direct stenting, 28.6% by balloon angioplasty followed by stenting, 10.1% by PCI without thrombus aspiration) or conventional PCI with balloon angioplasty followed by stenting. BMS were implanted in 92% of PCI procedures. All patients were treated with ASA, 600 mg of clopidogrel, UFH, and abciximab unless contraindicated. TIMI myocardial blush grade 0 or 1 occurred in 17.1% of patients with thrombus aspiration and 26.3% of those with conventional PCI (P<0.001). Complete resolution of ST-segment elevation occurred in 56.6% and 44.2%, respectively (P<0.001). Death, reinfarction, and TVR rates at 30 days were not significantly different (6.8% versus 9.4%) (17). However, at 1 year, rates of cardiac death (3.6% versus 6.7%, P=0.02) and cardiac death or nonfatal reinfarction (5.6% versus 9.9%, P=0.009) were lower with thrombus aspiration. Low myocardial blush grade and incomplete ST-segment resolution were associated with clinical events (102).

EXPIRA was a smaller (n=175) randomized clinical trial that also compared thrombus aspiration with conventional PCI, but only in patients with TIMI flow 0/1 (18). TIMI myocardial blush grade of 2 or more (88% versus 60%, P<0.001) and 90-minute ST-segment resolution greater than 70% (64% versus 39%, P<0.001) occurred more frequently in the thrombus aspiration group. Infarct size measured by contrast-enhanced magnetic resonance imaging in 75 patients at 3 months was significantly reduced only in the thrombus aspiration group.

Both of these trials, as well as a meta-analysis by Bavry et al (103) and a large pooled analysis of randomized trials (104), support the use of aspiration thrombectomy for STEMI. In developing a recommendation for the role of routine aspiration thrombectomy, however, it is noteworthy that TAPAS was a study of routine thrombus aspiration versus no thrombus aspiration rather than a study of routine thrombus aspiration versus selective thrombus aspiration. It is not known whether a strategy of selective thrombus aspiration in patients with a large thrombus burden might be superior to no thrombus aspiration or equivalent to routine thrombus aspiration. Clinically, it is reasonable to assume that this strategy can be useful in STEMI patients with short ischemic times and large thrombus burden. It may not be helpful in STEMI patients with long ischemic times, side branches with small infarct territories, or lesions with low thrombus burden.

8. Recommendations for the Use of Stents in STEMI

8.1. Stent Selection for STEMI

Primary PCI is generally the preferred reperfusion strategy for patients with STEMI (110). Compared with balloon angioplasty, routine BMS implantation during primary PCI decreases risk for TVR and possibly reduces MI rates but does not reduce mortality rates (111,112).

Two-year data from the Massachusetts registry (113) from 1221 propensity score–matched pairs of DES and BMS patients demonstrated a reduction in mortality and TVR rates with DES in primary PCI, and an analysis from the New York State registry (114) found a reduction in mortality rates but not TVR rates with DES. These reports were limited to patients treated before 2005, so they represent the earliest experience with DES, in which selection bias may have influenced stent choice and off-label use may have been pursued more cautiously. Additionally, duration of clopidogrel therapy was longer in the DES group.

More recently, several relatively small randomized clinical trials have shown an inconsistent efficacy for DES over BMS in primary PCI. Three meta-analyses of these trials have concluded that there were no differences in death, MI, or stent thrombosis rates, but TVR rates were decreased with DES (115–117). Variably included were 12 studies that differed in trial design, inclusion criteria, end-point definitions, stent types, duration of clopidogrel treatment, and type of follow-up (angiographic versus clinical). They were limited by sample size and duration of follow-up and by usually
Table 9. Recommendation for Angiography in Patients With Chronic Kidney Disease

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2. In chronic kidney disease patients undergoing angiography, isosmolar contrast agents are indicated and are preferred. (Level of Evidence: A)</td>
<td>1. In patients with chronic kidney disease undergoing angiography who are not undergoing chronic dialysis, either an isosmolar contrast medium (19,119) (Level of Evidence: A) or a low-molecular-weight contrast medium other than ioxaglate or iohexol is indicated (19). (Level of Evidence: B)</td>
<td>Modified recommendation (changed text).</td>
</tr>
</tbody>
</table>

PCI Focused Update Section

9. Recommendation for Angiography in Patients With Chronic Kidney Disease

(See Table 9.)

9.1. Angiography in Patients With Chronic Kidney Disease

Patients with chronic kidney disease (CKD) with or without diabetes who undergo angiography are at high risk for a contrast-induced nephropathy (CIN). At issue is the selection of a contrast agent to minimize this risk. The 2007 UA/NSTEMI guideline recommended that in patients with chronic kidney disease undergoing angiography, “isosmolar contrast agents are indicated and are preferred (Level of Evidence: A)” (p e112) (97). In patients with CKD or CKD and diabetes mellitus who are undergoing angiography, isosmolar contrast material was shown to lessen the rise in creatinine. This was based on evidence up to mid-2007 that suggested that isosmolar agents also reduced the risk of CIN in both a moderate-sized randomized clinical trial (RECOVER [Renal Toxicity Evaluation and Comparison Between Visipaque (Iodixanol) and Hexabrix (Ioxaglate) in Patients With Renal Insufficiency Undergoing Coronary Angiography]) that compared iodoxanil with ioxaglate (119) and a meta-analysis of 16 smaller, earlier clinical trials (120).

However, in mid-2007, a major US randomized trial of contrast agents in patients with CAD and an estimated glomerular filtration rate of 20 to 59 mL/min who were undergoing angiography, the CARE study, was published. CARE compared the low-osmolar agent iopamidol and the isosmolar agent ioxaglate and found no difference in the primary end point (serum creatinine increase of 0.5 mg/dL or higher over baseline) between iopamidol (4.4%) and ioxaglate (6.7%, P = 0.39) (19).

Since then, several larger randomized trials have been published that reported no difference in CIN when ioxaglate was compared with various other low-osmolar contrast media (LOCM) (19,121–123). These and other randomized trials comparing isosmolar iodoxanil with LOCM have been summarized in 2 mutually supportive and complementary meta-analyses involving 16 trials in 2763 patients (124) and 25 trials in 3260 patients (125), respectively. When more recent trials were combined with the older studies, trends in CIN favoring iodoxanil were no longer significant (summary RR 0.79; 95% CI 0.56 to 1.12; P = 0.29; summary RR 0.80; CI 0.61 to 1.04; P = 0.10, respectively) (124,125). However, subanalyses showed variations in relative renal safety by specific LOCM: A reduction in CIN was observed when iodoxanil was compared with ioxaglate, the only ionic LOCM (RR 0.58, CI 0.37 to 0.92, P = 0.02 (124), and with iohexol, a nonionic LOCM (RR 0.19 to 0.38, P < 0.01) (124,125), but no difference was noted in comparisons of iodoxanil with iopamidol, iopromide, or ioversal (124), and a single trial favored iomepril (123). A pooled comparison of iodoxanil with all nonionic LOCM other than iohexol indicated equivalent safety (RR 0.97; CI 0.72 to 1.32, P = 0.86) (125). Results were consistent regardless of ancillary preventive therapies (hydration, acetylcysteine), route of administration (intravenous or intra-arterial), age, sex, dose, or preexisting CKD or diabetes. Of further interest, findings were similar in the 8 studies (n = 1793 patients) performed in the setting of coronary angiography (124).

These more recent observations indicate that the CIN risk of contrast media cannot be attributed to osmolarity alone, but that ionicity and other and unknown characteristics of spe-
Routine assessment with intracoronary physiological measurements (Doppler ultrasound, fractional flow reserve) in the assessment of the effects of intermediate coronary stenoses (30% to 70% luminal narrowing) in patients with anginal symptoms. Coronary pressure or Doppler velocimetry may also be useful as an alternative to performing noninvasive functional testing (e.g., when the functional study is absent or ambiguous) to determine whether an intervention is warranted. (Level of Evidence: B)

**10. Recommendations for Use of Fractional Flow Reserve**

**(See Table 10.)**

**10.1. Fractional Flow Reserve**

Coronary angiography is often performed in clinical situations in which preprocedural functional testing has not been obtained. Additionally, in the setting of multivessel disease, the need to treat individual stenosis is often difficult to determine. Although revascularization of ischemia-producing lesions improves patient outcomes, the clinical benefits of revascularization of stenotic but non–ischemia-producing lesions are less clear. Intraprocedural assessment of the functional significance of individual stenosis may help define the optimal revascularization strategy.

The objective of the FAME trial (20) was to compare clinical outcomes after PCI on the basis of conventional angiographic determination of lesion severity versus fractional flow reserve (FFR) combined with angiography in patients with multivessel disease. This prospective, randomized, multicenter trial included 1005 patients selected from 1905 screened patients at 20 medical centers who were randomized to either angiography-guided or FFR-guided (for lesions with FFR less than or equal to 0.80) PCI. Before randomization, lesions that required PCI were prespecified on the basis of the angiographic appearance. Patients assigned to angiography-guided PCI had all identified lesions treated with DES, whereas those assigned to FFR-guided PCI had only identified lesions with an FFR of 0.80 or less.

The results of the FAME trial suggest that identification of ischemia-producing lesions by use of systematic assessment of FFR in patients undergoing multivessel PCI is associated with improved clinical outcomes compared with angiographic assessment alone. Further evidence is needed regarding the added value of assessing FFR in lesions with greater than 90% stenosis.

**11. Recommendations for PCI for Unprotected Left Main Coronary Artery Disease**

**(See Table 11.)**

**11.1. Unprotected Left Main Coronary Artery Disease**

Although listed as a Class III indication in the 2003 guideline on the management of chronic stable angina (145), PCI of an unprotected left main coronary artery has increased in frequency (146). Early studies (listed in Appendix 6) involved short follow-up periods, which gave CABG a disadvantage, because the apparent benefits of surgery over PCI in other settings have not typically been fully evident until 1 to 5 years after the procedure. In the ACC/AHA/SCAI 2005 guideline...
update for PCI, the performance of PCI for left main CAD is given a Class III, Level of Evidence C recommendation if the patient is eligible for CABG and a Class IIa, Level of Evidence B recommendation for patients who are not eligible for CABG. Thus, it has been recommended that CABG still be considered the standard of care for left main CAD (147–149).

Several studies comparing CABG to PCI, however, indicated that the advantage of CABG consists primarily of fewer repeat revascularizations (139,149–155). The study by Brener et al (156) indicates no significant mortality difference between PCI and CABG after 3 years of follow-up. Longer-term follow-up is needed.

The present focused update specifically addresses the findings of SYNTAX, an unblinded, randomized clinical trial that assigned patients with 3-vessel and/or left main CAD to an initial treatment strategy of CABG or PCI (21). The primary prespecified end point for the 1800 enrolled patients was the composite of death, stroke, and myocardial revascularization determined at 12 months. Prespecified stratification occurred for diabetes mellitus and left main CAD. Ninety-seven percent of CABG patients received at least 1 arterial graft.

In SYNTAX, for the subgroup with left main CAD, there were no significant differences in the incidence of the composite end point (death, MI, stroke, or repeat revascularization) between the 2 groups (PCI 15.8% versus CABG 13.7%, P=0.44), although rates of repeat revascularization were higher (11.8% versus 6.5%, P=0.02) and rates of stroke were lower (0.3% versus 2.7%, P=0.01) in the PCI group (21). Left main stented patients with limited CAD (lower SYNTAX score) displayed a trend toward fewer adverse events at 12 months than did similar patients assigned to CABG. Specifically, MACE in patients with isolated left main CAD occurred in 8.5% with CABG versus 7.1% with PCI, and in 13.2% with CABG versus 7.5% with PCI in patients with left main CAD and disease of 1 other vessel. In contrast, MACE with CABG versus PCI were numerically less frequent in patients with disease of the left main coronary artery and disease of 2 other vessels (14.4% versus 19.8%) and in patients with both left main CAD and 3 other vessels involved (15.4% versus 19.3%) (21).

These data from a post hoc subgroup analysis in SYNTAX must be interpreted with caution for several reasons. The number of patients with isolated left main (or left main plus single vessel) CAD was relatively small, and the differences in outcomes were not statistically significant. Furthermore, SYNTAX reported outcomes at 1 year, and longer follow-up is needed before left main PCI (in patients who are otherwise surgical candidates) should become standard clinical practice. Moreover, because the overall study did not reach its primary end point, subset analyses are less robust; because noninferiority was not proven in this cohort, specific information for each subgroup is of an observational nature and is hypothesis-generating.

On the basis of the evidence in aggregate, prior to and within the present focused update, the writing group has modified the class of recommendation for PCI to unprotected left main coronary artery disease as follows:

### Table 11. Recommendations for PCI for Unprotected Left Main Coronary Artery Disease

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Class IIa</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. It is reasonable that patients undergoing PCI to unprotected left main coronary obstructions be followed up with coronary angiography between 2 and 6 months after PCI. <em>(Level of Evidence: C)</em></td>
<td>Deleted recommendation (no longer recommended).</td>
<td></td>
</tr>
<tr>
<td><strong>Class IIb</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. PCI of the left main coronary artery with stents as an alternative to CABG may be considered in patients with anatomic conditions that are associated with a low risk of PCI procedural complications and clinical conditions that predict an increased risk of adverse surgical outcomes (21,138,139)* <em>(Level of Evidence: B)</em></td>
<td>New recommendation</td>
<td></td>
</tr>
<tr>
<td><strong>Class III</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2005 PCI Guideline, Section 5.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCI is not recommended in patients with [<em>...</em>]</td>
<td>Modified recommendation (bullet “f” from Sections 5.1 and bullet “e” from Sections 5.2 and 5.3 are no longer current; see 2009 Class IIb recommendation #1).</td>
<td></td>
</tr>
<tr>
<td>2005 PCI Guideline, Sections 5.2, 5.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>e. Left main disease and eligibility for CABG. <em>(Level of Evidence: C)</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Stenting for unprotected left main CAD is relatively more favorable for patients with isolated left main coronary artery lesions or left main coronary artery plus single-vessel disease (21), for patients with ostial or mid left main coronary artery lesions (138,140–144), and for patients with factors (such as severe lung disease, prior thoracic surgery, or poor bypass graft targets) that would make CABG a high-risk procedure or unlikely to be successful. Conversely, CABG surgery for unprotected left main CAD may be relatively more favorable for patients with left main CAD plus multivessel disease (21), distal/bifurcation left main coronary artery lesions (138,140–144), or low surgical risk with a good chance of technical success.
left main coronary from Class III to Class IIb, now citing the Level of Evidence as B. The writing group noted 3 important caveats in classifying unprotected left main CAD as a Class IIb indication. First, patients undergoing PCI in cohort or randomized studies represent merely a subset of all patients with left main CAD. Because only certain left main coronary lesions are amenable to PCI, the Class IIb indication is intended to apply only to those left main lesions that are suitable for PCI. The primary conclusion of SYNTAX is that PCI failed to be shown to be noninferior to CABG in left main and triple-vessel disease. Because patients in SYNTAX with left main and 2- or 3-vessel disease compared with patients with left main and no other vessel or 1-vessel disease had higher rates of MACE, it is recommended that PCI to left main lesions be limited to patients without significant multivessel disease. Second, because of the narrow margin for error, operators undertaking PCI of left main coronary lesions should be experienced and backed by highly competent support staff and surgeons (157). Although routine use of intravascular ultrasound has been advocated by some authors for the evaluation of left main lesions, there is no definitive evidence at present that this technique improves outcomes (138,157). Finally, not all left main lesions respond equally well to PCI. Bifurcation lesions are technically more challenging (138) and have higher rates of restenosis (140,141,143,144). In contrast, results of PCI of ostial or mid-body left main coronary lesions more closely approximate the results of CABG, even with respect to the need for subsequent procedures (142). The best case for PCI as an alternative to CABG for left main CAD is in ostial and mid-body lesions without additional multivessel disease.

The writing group discussed the previous Class IIa recommendation for follow-up between 2 and 6 months with coronary angiography. They focused on the inability of angiography to predict a situation that might be prone to acute, sudden stent thrombosis, as well as the risk associated with angiography in a patient who has undergone placement of a left main stent. In view of these factors, the writing group decided that the Class IIa recommendation for angiographic follow-up should be omitted from the guidelines.

### 12. Recommendations for the Timing of Angiography and Antiplatelet Therapy in UA/NSTEMI

(See Table 12.)

#### 12.1. Timing of Angiography

A routine invasive strategy in UA/NSTEMI patients with high-risk features has been associated with improved outcomes, but the optimal timing of intervention has not been well established. Early intervention might prevent ischemic events that could occur while the patient awaits a delayed procedure. Alternatively, with intensive antithrombotic therapy with a delay for up to a few days, procedure-related complications might be avoided by intervening on a more stable, “passivated” plaque. Although one study has suggested greater benefit with relatively early intervention (106), the evidence base for a definitive recommendation on timing is weak. Thus, the question of when to intervene in UA/NSTEMI has not been answered conclusively. Given this uncertainty, the TIMACS investigators (23) undertook a large, multicenter randomized trial to determine whether a strategy of early coronary angiography and intervention was superior to a delayed strategy in patients with UA/NSTEMI assigned to an invasive approach.

TIMACS randomly assigned 3031 non–ST-elevation ACS patients to routine early intervention (coronary angiography within 24 hours) or to delayed intervention (coronary angiography at 36 hours or more). The primary outcome was the composite of death, MI, or stroke at 6 months, and a prespecified secondary outcome was death, MI, or refractory ischemia (23).

Coronary angiography was performed at a median of 14 hours in the early-intervention group and 50 hours in the delayed-intervention group. At 6 months, 9.7% of patients in the early-intervention group experienced a primary outcome versus 11.4% in the delayed-intervention group (HR 0.85; 95% CI 0.68 to 1.06; P=0.15). Death, MI, or refractory ischemia was reduced by 28% in favor of early intervention (9.6% versus 13.1%; HR 0.72; 95% CI 0.58 to 0.89; P=0.002). Prespecified analyses showed that early intervention improved the primary outcome in the one third of patients at highest risk (HR 0.65; 95% CI 0.48 to 0.88), as determined by a GRACE (Global Registry of Acute Coronary Events) risk score greater than 140, but not in the two...
thirds at low to intermediate risk (HR 1.14; 95% CI 0.82 to 1.58; \(P\) for heterogeneity=0.01). There were no safety issues related to early intervention; major bleeding occurred in 3.1% of patients in the early invasive group and 3.5% in the delayed invasive group.

Overall in TIMACS, early intervention trended to be superior to delayed intervention in preventing the composite of death, MI, or stroke (primary end point), but the difference was not statistically significant (23). However, early intervention reduced the composite of death, MI, or refractory ischemia (the secondary end point) and, in high-risk patients, was superior to a delayed invasive strategy. The trial was underpowered to discern a clinically meaningful 15% advantage to early invasive therapy for the primary end point, with recruitment stopped at 3000 because of recruitment and funding challenges. This provided a power of 80% to detect a risk reduction of 28% in the primary end point. Subgroup analysis (high-risk subset) of this overall negative trial was not robust and must be viewed cautiously.

Taken together with the earlier ISAR-COOL (Intracoronary Stenting With Antithrombotic Regimen Cooling Off) study (106), the favorable secondary end-point results, the subgroup analysis in patients at higher risk, and the lack of a safety issue with early therapy, TIMACS suggests the following conclusions: an early invasive strategy within 12 to 24 hours (median 14 hours) is preferred in high-risk patients and may be chosen in patients at low to intermediate risk at the physician’s or institution’s preference (e.g., efficiency and cost savings), whereas a more delayed approach may be beneficial in low- to intermediate-risk patients (23). In contrast, results from the recent ABOARD (Angioplasty to Blunt the rise Of troponin in Acute coronary syndromes Randomized for an immediate or Delayed intervention) trial (160) indicate that an immediate invasive strategy (median time 1.1 hour) in UA/NSTEMI is not associated with further incremental benefit.

Typically, early versus delayed angiography is defined with reference to a 12- to 48-hour time window. The ISAR-COOL study (106) supports an earlier compared with a more delayed time to angiography, but the data supporting this general timing suggestion are limited.

12.2. Timing of GP IIb/IIIa Receptor Antagonist Therapy in UA/NSTEMI Patients Undergoing Angiography

The optimal timing of initiation of GP IIb/IIIa receptor antagonist therapy in patients with UA/NSTEMI (i.e., whether to administer therapy upstream on presentation or later at the time of angiography/PCI) and the optimal application of this therapy (i.e., whether routine, selective, or provisional) have not been resolved. The 2007 ACC/AHA Guidelines for the Management of Patients With UA/NSTEMI recommend that patients with definite or likely UA/NSTEMI selected for an invasive approach should receive ASA and either clopidogrel or a GP IIb/IIIa receptor antagonist before angiography (Class I, Level of Evidence: A) (97). They further state that it is reasonable to initiate both clopidogrel and a GP IIb/IIIa receptor antagonist, especially in the setting of delays to angiography, high-risk features, or recurrent ischemic discomfort (Class IIa, Level of Evidence: B).

The 2007 European Society of Cardiology guidelines recommend early dual-antiplatelet therapy with ASA and clopidogrel (Class I), with the addition of a GP IIb/IIIa receptor antagonist for those patients with the specific high-risk features of an elevated troponin level, ST-segment depression, or diabetes (Class IIa) (163).

The EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome) trial (22) tested the hypothesis that a strategy of early, routine administration of the GP IIb/IIIa receptor antagonist eptifibatide would be superior to delayed, provisional administration in reducing ischemic complications among high-risk patients. EARLY ACS enrolled 9492 non–ST-segment elevation ACS (UA/NSTEMI) patients who presented within 24 hours of an episode of ischemic rest discomfort and who were assigned to an invasive treatment strategy no sooner than the next calendar day (amended later to at least 12 hours but less than 96 hours after randomization). Eligibility required at least 2 of the following features: ST-segment depression or transient ST-segment elevation, an elevated biomarker (creatine kinase-MB or troponin), and age of 60 years or older (amended to include patients 50 to 59 years with known vascular disease). The key primary end point was all-cause death, MI, recurrent ischemia that required urgent revascularization, or thrombotic bailout at 96 hours. The key secondary efficacy end point was all-cause death or MI within 30 days. Safety end points included major hemorrhage and transfusions through 120 hours after randomization. The study was powered to detect 22.5% and 15% relative reductions in the primary and key secondary end points, respectively.

The primary end point occurred in 9.3% of patients in the early therapy arm versus 10.0% of patients in the provisional GP IIb/IIIa therapy arm (odds ratio 0.92; 95% CI 0.80 to 1.06; \(P=0.23\)). Secondary end-point event rates were 11.2% versus 12.3% (odds ratio 0.89; CI 0.79 to 1.01; \(P=0.08\)). Early, routine eptifibatide administration occurred at the cost of a greater risk of TIMI major hemorrhage (2.6% versus 1.8%, \(P=0.02\)). Moderate and less severe bleeding also occurred more commonly. Rates of red cell transfusion were 8.6% and 6.7%, respectively (\(P=0.001\)).

EARLY ACS represents a large, carefully executed trial with potentially important implications; however, these results are best taken in the context of previous major trials. As a single trial, EARLY ACS does not establish the superiority of early versus delayed, provisional eptifibatide in non–ST-elevation ACS. A trend toward fewer recurrent ischemic complications was noted at 30 days, but this was counterbalanced by more frequent episodes of bleeding and need for transfusions. Given the use of eptifibatide at PCI (39% of patients in the delayed, provisional group), EARLY ACS does not contradict the benefit of GP IIb/IIIa therapy over placebo in UA/NSTEMI in previous studies. Rather, its findings relate specifically to the timing of such therapy and selective versus routine use.

In another similar study, ACUITY (Acute Catheterization and Urgent Intervention Triage strategY), superiority of early GP IIb/IIIa therapy also was not found, but investigators could not exclude as much as a 29% benefit with GP IIb/IIIa therapy nor show noninferiority of delayed administration. In addition, drug exposure before angiography was much shorter.
(4 hours), which might substantially diminish the opportunity for differential efficacy (161).

The results of the EARLY ACS study are similar to a meta-analysis of 6 prior large, randomized trials of GP IIb/IIIa therapy versus placebo in non–ST-elevation ACS in which an invasive strategy was not mandated, which showed a relative reduction in death/MI of 9% (CI 2% to 16%) (162). In those patients who underwent PCI, the RR reduction was a more robust 23% (CI 8% to 36%). This finding also was consistent with EARLY ACS. Both studies found no benefit in troponin-negative patients. The investigators ascribed the less than expected benefit of early GP IIb/IIIa therapy in EARLY ACS to convergence of eptifibatide use in the 2 arms at the time of PCI and more aggressive contemporary cotherapies compared with earlier studies, including frequent use of clopidogrel, low-molecular-weight heparin, and statins. A further caution is the lack of follow-up for several years.

Despite a lack of clarity from the overall and subgroup results, an argument can be made against the routine upstream use of GP IIb/IIIa therapy in all non–ST-elevation ACS patients intended for an invasive strategy. In particular, those with a normal baseline troponin level and those over the age of 75 years, in whom there was no evidence for benefit but who showed an increased risk of bleeding, might be excluded. On the other hand, findings in those with a positive troponin at baseline and those with diabetes, although not definitive in EARLY ACS alone, trend positively and are in line with previous results. The EARLY ACS trial showed no significant benefit in the composite outcome comparing early versus delayed eptifibatide as defined by the study. Thus, at this time, a high-risk group that would clearly benefit from the early administration of eptifibatide upstream before cardiac catheterization has not been identified. Early GP IIb/IIIa therapy in patient groups continues to appear reasonable if they are judged clinically to be at high risk of thrombotic events relative to bleeding risk.

Staff

American College of Cardiology Foundation
John C. Lewin, MD, Chief Executive Officer
Charlene May, Senior Director, Science and Clinical Policy
Lisa Bradfield, CAE, Associate Director, Science and Clinical Policy
Leigh Maltese, Specialist, Science and Clinical Policy
Debjani Mukherjee, MPH, Associate Director, Evidence-Based Medicine
Erin A. Barrett, Senior Specialist, Science and Clinical Policy

American Heart Association
Nancy Brown, Chief Executive Officer
Rose Marie Robertson, MD, FACC, FAHA, Chief Science Officer
Judy Bezanson, DSN, CNS, RN, Senior Science and Medicine Advisor
## Appendix 1. Author Relationships With Industry and Other Entities—ST-Elevation Myocardial Infarction

<table>
<thead>
<tr>
<th>Writing Group Member</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speaker</th>
<th>Ownership/Partnership/Principal</th>
<th>Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frederick G. Kushner, Co-Chair</td>
<td>Tulane University School of Medicine—Clinical Professor of Medicine; Heart Clinic of Louisiana—Medical Director</td>
<td>None</td>
<td>Abbott; Bristol-Myers Squibb</td>
<td>None</td>
<td>Daiichi-Sankyo</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Mary Hand, Co-Chair</td>
<td>Agency for Healthcare Research and Quality—Health Science Administrator</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Elliott M. Antman</td>
<td>Brigham and Women’s Hospital</td>
<td>Momenta Pharmaceuticals; Sanofi-aventis</td>
<td>Eli Lilly; Sanofi-aventis</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Eric R. Bates</td>
<td>University of Michigan—Professor of Medicine</td>
<td>Bristol-Myers Squibb; Daiichi-Sankyo; Eli Lilly; Novartis; Takeda</td>
<td>Boehringer Ingelheim; Daiichi-Sankyo; Eli Lilly; Sanofi-aventis</td>
<td>None</td>
<td>Eli Lilly*</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Donald E. Casey, Jr</td>
<td>Atlantic Health—Chief Medical Officer and Vice President of Quality</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Lee A. Green</td>
<td>University of Michigan—Associate Professor, Dept. of Family Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Judith S. Hochman</td>
<td>New York University School of Medicine—Clinical Chief of Cardiology</td>
<td>GlaxoSmithKline</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Harlan M. Krumholz</td>
<td>Yale University School of Medicine—Harold H. Hines, Jr. Professor of Medicine and Epidemiology and Public Health</td>
<td>United Healthcare*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Joseph P. Smalo</td>
<td>Virginia Commonwealth University Health System—Professor and Chair, Dept. of Emergency Medicine</td>
<td>None</td>
<td>Bristol-Myers Squibb/Sanofi-aventis</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>David L. Pearle</td>
<td>Georgetown University Hospital—Professor of Medicine</td>
<td>None</td>
<td>None;</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Michael A. Sloan</td>
<td>University of South Florida—Professor and Director, UF Stroke Program</td>
<td>None</td>
<td>Boehringer Ingelheim; Genentech; National Association for Continuing Education</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Sidney C. Smith, Jr</td>
<td>Center for Cardiovascular Science and Medicine—Professor of Medicine; Director</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents the relationships of committee members with industry that were reported at the Task Force on Practice Guidelines meeting and updated in conjunction with all meetings. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity or ownership of $10,000 or more of the fair market value of the business entity, or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships noted in this table are modest unless otherwise noted.

*Significant (greater than $10,000) relationship.
### Appendix 2. Author Relationships With Industry and Other Entities—Percutaneous Coronary Intervention

<table>
<thead>
<tr>
<th>Writing Group Member</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speaker</th>
<th>Ownership/Partnership/Principal</th>
<th>Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sidney C. Smith, Jr. Chair</td>
<td>Center for Cardiovascular Science and Medicine—Professor of Medicine; Director</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Spencer B. King III, Co-Chair</td>
<td>Saint Joseph's Heart and Vascular Institute—President; Saint Joseph’s Health System—Executive Director, Academic Affairs</td>
<td>Medtronic*; MLV Therapeutics</td>
<td>Network for Continuing Medical Education*</td>
<td>None</td>
<td>Abbott; AngelMed; BG Medicine; Merck</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Jeffrey L. Anderson</td>
<td>Intermountain Medical Center—Associate Chief of Cardiology</td>
<td>BMS/Sanofi-aventis; Daiichi-Sankyo; Eli Lilly</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Steven R. Bailey</td>
<td>University of Texas Medical Center—Professor of Medicine and Radiology</td>
<td>Volcano Therapeutics</td>
<td>Abbott; BSCI; Cordis; Medtronic; Volcano Therapeutics</td>
<td>None</td>
<td>Abbott; BSCI; Cordis; Volcano Therapeutics</td>
<td>SCAI Fellows Grant*</td>
<td>None</td>
</tr>
<tr>
<td>James C. Blankenship</td>
<td>Geisinger Medical Center—Director, Cardiology; Director, Cardiac Cath Lab</td>
<td>None</td>
<td>Sanofi-aventis</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Alice K. Jacobs</td>
<td>Boston University School of Medicine—Professor of Medicine; Boston University Medical Center—Director, Cardiac Catheterization Laboratories and Interventional Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Abbott Vascular; Accumetrics; Cordis; Schering-Plough Research Institute</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Douglass A. Morrison</td>
<td>Yakima Heart Center—Interventional Cardiologist</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Eric D. Peterson</td>
<td>Duke Clinical Research Institute, Duke University Medical Center—Professor of Medicine; Director, Cardiovascular Research</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Bristol-Myers Squibb/Sanofi-aventis*; Merck*; Schering-Plough*</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Patrick L. Whitlow</td>
<td>Cleveland Clinic Foundation, Dept. of Cardiovascular Medicine—Director, Interventional Cardiology</td>
<td>None</td>
<td>None</td>
<td>ICON Plc; Medlogics; Medtronic</td>
<td>Edwards*; Evalve</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>David O. Williams</td>
<td>Brigham and Women’s Hospital</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Volcano Therapeutics</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

DSMB indicates data and safety monitoring board; and SCAI, Society for Cardiovascular Angiography and Interventions.

This table represents the relationships of committee members with industry that were reported at the Task Force on Practice Guidelines meeting and updated in conjunction with all meetings. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity or ownership of $10,000 or more of the fair market value of the business entity, or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships noted in this table are modest unless otherwise noted.

*Significant (greater than $10,000) relationship.
### Appendix 3. Reviewer Relationships With Industry and Other Entities—2009 STEMI and PCI Focused Updates

<table>
<thead>
<tr>
<th>External Reviewer</th>
<th>Representation</th>
<th>Consultant</th>
<th>Speaker</th>
<th>Ownership/Partnership/Principal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul W. Armstrong</td>
<td>Official Reviewer—AHA</td>
<td>Eli Lilly*, Ischemix LLC</td>
<td>None</td>
<td>None</td>
<td>Boehringer Ingelheim (Canada) Ltd*, Eli Lilly*, Portola Pharmaceuticals Inc*, Sanofi-aventis Canada Inc*; Schering-Plough Research Institute*; Uppsala Clinical Research Center and AstraZeneca*</td>
<td>None</td>
</tr>
<tr>
<td>Christopher E. Buller</td>
<td>Official Reviewer—ACCF/AHA Task Force on Practice Guidelines</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Craig B. Clark</td>
<td>Official Reviewer—ACCF Board of Governors</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Hani Jneid</td>
<td>Official Reviewer—AHA</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Sanjay Kaul</td>
<td>Official Reviewer—AHA</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Mikhail Kostiborod</td>
<td>Official Reviewer—AHA</td>
<td>Sanofi-aventis</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>George P. Rodgers</td>
<td>Official Reviewer—ACCF Board of Trustees</td>
<td>United Health Care</td>
<td>None</td>
<td>Biophysical*, Paragon Health</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Howard C. Hermann</td>
<td>Organizational Reviewer—SCAI</td>
<td>None</td>
<td>None</td>
<td>Johnson &amp; Johnson; Schering-Plough</td>
<td>Boston Scientific*; Medtronic*; The Medicines Co*</td>
<td>None</td>
</tr>
<tr>
<td>Joseph S. Alpert</td>
<td>Content Reviewer</td>
<td>Bayer; Boehringer Ingelheim; Exeter CME; Johnson &amp; Johnson; King Pharmaceutical; Novartis; Roche; Sanofi-aventis</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Jorge A. Belardi</td>
<td>Content Reviewer—ACCF Interventional Council</td>
<td>Boston Scientific; Medtronic</td>
<td>Boston Scientific; Medtronic</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Keith H. Benzuly</td>
<td>Content Reviewer—ACCF Interventional Council</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Deepak L. Bhatt</td>
<td>Content Reviewer</td>
<td>Arena; Astellas; AstraZeneca; Bristol-Myers Squibb; Daiichi-Sankyo; Eli Lilly; Johnson &amp; Johnson; Medtronic; Novartis; Otsuka; Portola; Sanofi-aventis</td>
<td>None</td>
<td>None</td>
<td>Bristol-Myers Squibb; Cogenex; Eli Lilly/Daiichi-Sankyo; Ethicon*; Heartscape*; Johnson &amp; Johnson; The Medicines Co; Momenta; Portola; Sanofi-aventis*; Sanofi/Bristol-Myers Squibb*; Takeda</td>
<td>None</td>
</tr>
<tr>
<td>Jeffrey C. Currenadi</td>
<td>Content Reviewer—ACCF Board of Governors</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>William E. Chavey</td>
<td>Content Reviewer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Jose A. Diez</td>
<td>Content Reviewer—ACCF Interventional Council</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>John U. Duherty</td>
<td>Content Reviewer—ACCF Board of Governors</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Steven M. Ellinger</td>
<td>Content Reviewer—ACCF/AHA Task Force on Practice Guidelines</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

(Continued)
## Appendix 3. Continued

<table>
<thead>
<tr>
<th>External Reviewer</th>
<th>Representation</th>
<th>Consultant</th>
<th>Speaker</th>
<th>Ownership/Partnership/Principal</th>
<th>Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Theodore Feldman</td>
<td>Content Reviewer</td>
<td>Abbott Vascular; Boston Scientific</td>
<td>Boston Scientific</td>
<td>Abbott Vascular; Boston Scientific</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Robert A. Guyton</td>
<td>Content Reviewer—ACCF/AHA Task Force on Practice Guidelines</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Robert A. Harrington</td>
<td>Content Reviewer</td>
<td>AstraZeneca; Baxter; Bayer; Bristol-Myers Squibb; Daiichi-Sankyo; Eli Lilly; Johnson &amp; Johnson; Medtronic; Ostuka Maryland Research Institute; Pfizer; Sanofi-aventis; Schering-Plough*; WebMD*</td>
<td>None</td>
<td>None</td>
<td>AstraZeneca; Baxter; Bristol-Myers Squibb*; GlaxoSmithKline*; The Medicines Co; Merck*; Portola*; Schering-Plough*</td>
<td>Duke Clinical Research Institute</td>
<td>None</td>
</tr>
<tr>
<td>Judith S. Hochman</td>
<td>Content Reviewer—ACCF/AHA Task Force on Practice Guidelines</td>
<td>GlaxoSmithKline</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Bayer Healthcare AG; Eli Lilly; GlaxoSmithKline; Johnson &amp; Johnson Pharmaceutical Research &amp; Development; Millennium Pharmaceuticals; Schering-Plough Research Institute</td>
<td>None</td>
</tr>
<tr>
<td>Adolf M. Hutter</td>
<td>Content Reviewer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Morton J. Kern</td>
<td>Content Reviewer</td>
<td>Merit Medical*; Radi Medical*; Volcano Therapeutics</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Richard J. Kovacs</td>
<td>Content Reviewer—ACCF Board of Governors</td>
<td>Eli Lilly</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Michel R. Le May</td>
<td>Content Reviewer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>David C. May</td>
<td>Content Reviewer—ACCF Board of Governors</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Michael R. McGuire</td>
<td>Content Reviewer—ACCF Board of Governors</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>J. Brent Muhlestein</td>
<td>Content Reviewer—ACCF Board of Governors</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Sibari S. Naidu</td>
<td>Content Reviewer—ACCF Interventional Council</td>
<td>Abiomed</td>
<td>Abbott Vascular; Cordis; Medtronic Cardiovascular</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Sharon-Lise T. Normand</td>
<td>Content Reviewer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Massachusetts Department of Public Health</td>
<td>None</td>
</tr>
<tr>
<td>Patrick T. O’Gara</td>
<td>Content Reviewer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

(Continued)
### Appendix 3. Continued

<table>
<thead>
<tr>
<th>External Reviewer</th>
<th>Representation</th>
<th>Consultant</th>
<th>Ownership/Partnership/Principal</th>
<th>Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carl J. Pepine</td>
<td>Content Reviewer</td>
<td>Abbott Vascular; Baxter Healthcare; Boehringer Ingelheim; CV Therapeutics; NicOx; Pfizer; Sanofi-aventis; Schering-Plough</td>
<td>None</td>
<td>None</td>
<td>Abbott Vascular; AstraZeneca; Baxter Healthcare; Berlex Labs/Bayer Healthcare; Boehringer Ingelheim; Cardium Therapeutics; CV Therapeutics; Daiichi-Sankyo/Lilly; Forest Labs; GlaxoSmithKline; Merck; Novartis; Pfizer; Reliant Pharmaceuticals; Sanofi-aventis; Schering-Plough; The Medicines Co; Vion Therapeutics; Wyeth-Ayerst Labs</td>
<td>None</td>
</tr>
<tr>
<td>Charanjit S. Rihal</td>
<td>Content Reviewer—ACCF Interventional Council</td>
<td>Cordis</td>
<td>None</td>
<td>None</td>
<td>Medtronic</td>
<td>None</td>
</tr>
<tr>
<td>Ray W. Squires</td>
<td>Content Reviewer—ACCF Interventional Council</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Bonnie H. Weiner</td>
<td>Content Reviewer—ACCF Imaging Council</td>
<td>Boston Biomedical Associates*; CR Bard*; Davol*; Lab Coat*; TherOx*</td>
<td>None</td>
<td>Imaging Core Lab Services*</td>
<td>Abbott Vascular; Boston Scientific; Medtronic</td>
<td>SCAI</td>
</tr>
<tr>
<td>Nanette K. Wenger</td>
<td>Content Reviewer</td>
<td>Abbott Vascular; AstraZeneca; Boston Scientific; Genzyme; Gilead Sciences; Medtronic; Merck; Pfizer; Schering-Plough*</td>
<td>None</td>
<td>None</td>
<td>Abbott Vascular*; Eli Lilly*; Gilead Sciences*; Merck*; NHLBI*; Pfizer*; Sanofi-aventis*</td>
<td>None</td>
</tr>
<tr>
<td>Harvey D. White</td>
<td>Content Reviewer</td>
<td>GlaxoSmithKline; Sanofi-aventis</td>
<td>None</td>
<td>None</td>
<td>AstraZeneca*; Daiichi-Sankyo*; Eli Lilly*; GlaxoSmithKline*; Johnson &amp; Johnson*; Merck Sharp &amp; Dohme*; The Medicines Co*; NIH*; Pfizer*; Roche*; Sanofi-aventis*; Schering-Plough*</td>
<td>None</td>
</tr>
<tr>
<td>Kim A. Williams</td>
<td>Content Reviewer—ACCF Imaging Council</td>
<td>Astellas Healthcare*; GE Healthcare*; King Pharmaceuticals*</td>
<td>None</td>
<td>None</td>
<td>GE Healthcare*; Molecular Insight Pharmaceuticals*</td>
<td>Molecular Insight</td>
</tr>
</tbody>
</table>

ACCF indicates American College of Cardiology Foundation; AHA, American Heart Association; NHLBI, National Heart, Lung, and Blood Institute; NIH, National Institutes of Health; and SCAI, Society for Cardiovascular Angiography and Interventions.

This table represents the relationships of peer reviewers with industry and other entities that were reported by authors to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity or ownership of $10 000 or more of the fair market value of the business entity, or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted.

*Significant (greater than $10 000) relationship.
### Appendix 4. Dosing Table for Antiplatelet and Anticoagulant Therapy Discussed in This Focused Update to Support PCI in STEMI

<table>
<thead>
<tr>
<th>Drug*</th>
<th>During PCI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Patient Received Initial Medical Treatment (With an Anticoagulant and/or Fibrinolytic Therapy)</td>
</tr>
<tr>
<td></td>
<td>Patient Did Not Receive Initial Medical Treatment (With an Anticoagulant and/or Fibrinolytic Therapy)</td>
</tr>
<tr>
<td></td>
<td>Comments: All Patients to Receive ASA (162–325 mg)</td>
</tr>
<tr>
<td><strong>Glycoprotein IIb/IIIa Receptor Antagonists (Section 2)</strong></td>
<td></td>
</tr>
<tr>
<td>Abciximab</td>
<td>Of uncertain benefit</td>
</tr>
<tr>
<td></td>
<td>Continue for up to 12 hours at the discretion of the physician (9,11).</td>
</tr>
<tr>
<td>Eptifibatide</td>
<td>Of uncertain benefit</td>
</tr>
<tr>
<td></td>
<td>Increased dosing over previous recommendation (11,12).</td>
</tr>
<tr>
<td>Tiroliban</td>
<td>Of uncertain benefit</td>
</tr>
<tr>
<td></td>
<td>Continue for up to 18 hours at the discretion of the physician (12).</td>
</tr>
<tr>
<td><strong>Thienopyridines (Section 3)</strong></td>
<td></td>
</tr>
<tr>
<td>Clopidogrel†</td>
<td>If 600 mg given orally, then no additional treatment A second LD of 300 mg may be given orally to supplement a prior LD of 300 mg (Class I, LOE: C)</td>
</tr>
<tr>
<td></td>
<td>Optimum LD has not been established. Dose for patients &gt;75 years of age has not been established. There is a recommended duration of therapy for all post-PCI patients receiving a BMS or DES. Period of withdrawal before surgery should be at least 5 days. (For full explanations, see footnote.)</td>
</tr>
<tr>
<td>Prasugrel‡</td>
<td>No data are available to guide decision making</td>
</tr>
<tr>
<td></td>
<td>There is no clear need for treatment with prasugrel before PCI. MD of 5 mg orally per day in special circumstances. Special dosing for patients &lt;60 kg or &gt;75 years of age. There is a recommended duration of therapy for all post-PCI patients receiving a DES. Contraindicated for use in patients with prior history of TIA or stroke. (For full explanations, see footnote.)</td>
</tr>
<tr>
<td><strong>Parenteral Anticoagulants (Section 4)</strong></td>
<td></td>
</tr>
<tr>
<td>Bivalirudin</td>
<td>For patients who have received UFH, wait 30 minutes, then give 0.75 mg/kg bolus, then 1.75 mg/kg per hour infusion (Class I, LOE: B)</td>
</tr>
<tr>
<td></td>
<td>Bivalirudin may be used to support PCI and STEMI with or without previously administered UFH with the addition of 600 mg of clopidogrel (9). In STEMI patients undergoing PCI who are at high risk of bleeding, bivalirudin anticoagulation is reasonable (9). (Continued)</td>
</tr>
</tbody>
</table>
During PCI

<table>
<thead>
<tr>
<th>Drug*</th>
<th>Patient Received Initial Medical Treatment (With an Anticoagulant and/or Fibrinolytic Therapy)</th>
<th>Patient Did Not Receive Initial Medical Treatment (With an Anticoagulant and/or Fibrinolytic Therapy)</th>
<th>Comments: All Patients to Receive ASA (162–325 mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>UFH</td>
<td>IV GP lib/llla planned: target ACT 200–500 seconds</td>
<td>IV GP lib/llla planned: 50–70 U/kg bolus to achieve an ACT of 200–50</td>
<td></td>
</tr>
<tr>
<td></td>
<td>No IV GP lib/llla planned: target ACT 250–300 seconds</td>
<td>No IV GP lib/llla planned: 70–100 U/kg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>seconds for HemoTec, 300–50 seconds for HemoTec</td>
<td>bolus to achieve target ACT of 250–300 seconds for HemoTec, 300–50 seconds for HemoTec</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hemochron (Class 1, LOE: C)</td>
<td>HemoTec (Class I, LOE: C)</td>
<td></td>
</tr>
</tbody>
</table>

ACT indicates activated clotting time; BMS, bare-metal stent; CABG, coronary artery bypass graft; DES, drug-eluting stent; GP, glycoprotein; IV, intravenous; LD, loading dose; LOE, level of evidence; MACE, major adverse cardiac events; MD, maintenance dose; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; TIA, transient ischemic attack; and UFH, unfractionated heparin.

*This list is in alphabetical order and is not meant to indicate a particular therapy preference. This drug table does not make recommendations for combinations of listed drugs. It is only meant to indicate approved dosages if a drug is chosen for a given situation.

†The optimum LD of clopidogrel has not been established. Randomized trials establishing its efficacy and providing data on bleeding risks used an LD of 300 mg orally followed by a daily oral dose of 75 mg (26,27). Higher oral LDs such as 600 mg or more than 900 mg (36) of clopidogrel more rapidly inhibit platelet aggregation and achieve a higher absolute level of inhibition of platelet aggregation, but the additive clinical efficacy and safety of higher oral LD have not been rigorously established. For post-PCI patients receiving a DES, a daily MD should be given for at least 12 months unless the risk of bleeding outweighs the anticipated net benefit afforded by a thienopyridine. For post-PCI patients receiving a BMS, an MD should be given for a minimum of 1 month (28) and ideally up to 12 months (unless the risk of bleeding outweighs the anticipated net benefit afforded by a thienopyridine; then it should be given for a minimum of 2 weeks). The necessity for giving an LD of clopidogrel before PCI is driven by the pharmacokinetics of clopidogrel, for which a period of several hours is required to achieve desired levels of platelet inhibition. Patients who have a reduced-function CYP2C19 allele have significantly lower levels of the active metabolite of clopidogrel, diminished platelet inhibition, and a higher rate of MACE, including stent thrombosis (53). In STEMI patients taking clopidogrel for whom CABG is planned and can be delayed, it is reasonable to discontinue the clopidogrel to allow for dissipation of the antiplatelet effect, unless the urgency for revascularization and/or the net benefit of clopidogrel outweighs the potential risks of excess bleeding. The period of withdrawal should be at least 5 days in patients receiving clopidogrel (30). Clopidogrel LD after fibrinolytic therapy:

‡The effectiveness and safety of the 5-mg dose have not been studied prospectively. For post-PCI patients receiving a DES, a daily MD should be given for at least 12 and up to 15 months unless the risk of bleeding outweighs the anticipated net benefit afforded by a thienopyridine. Do not use prasugrel in patients with active pathological bleeding or a history of prior MI for which its effect appears to be greater and its use may be considered. Do not start prasugrel in patients likely to undergo urgent CABG. When possible, discontinue prasugrel at least 7 days before any surgery. Additional risk factors for bleeding include body weight <60 kg, propensity to bleed, concomitant use of medications that increase the risk of bleeding (e.g., warfarin, heparin, fibrinolytic therapy, or chronic use of nonsteroidal antiinflammatory drugs).
Appendix 6. Outcomes of PCI Versus CABG for Unprotected Left Main Coronary Artery Disease

<table>
<thead>
<tr>
<th>Reference, Year</th>
<th>Type of Study, Years of Recruitment</th>
<th>PCI/CABG</th>
<th>Short-Term Results</th>
<th>Long-Term Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chieffo et al (141), 2006</td>
<td>Cohort, 2002–4</td>
<td>107/142</td>
<td><em>In-hospital outcomes for PCI versus CABG:</em> Death: 0% versus 2.1%; P=NS; MI: 9.3% versus 26.1%; P=0.0009; Stroke: 0% versus 2%; P=NS</td>
<td>1-Year adjusted ORs for PCI versus CABG: Death or MI: 0.26; 95% CI 0.078–0.597; P=0.0005; Death, MI, or stroke: 0.385; 95% CI 0.180–0.819; P=0.01</td>
</tr>
<tr>
<td>Lee et al (151), 2006</td>
<td>Cohort, 2003–5</td>
<td>50/123</td>
<td>30-Day outcomes for PCI versus CABG: Death: 2% versus 5%; P=NS; MI: 0% versus 2%; P=NS; Stroke: 0% versus 8%; P=0.03; Death/MI/stroke/revascularization: 17% versus 2%; P&lt;0.01</td>
<td>1-Year follow-up for PCI versus CABG: Death: 4% versus 15%; P=0.2; MI: stroke: 4% versus 21%; HR=4.4; 95% CI 1.0–16.6; P=0.03; Revascularization: 13.3% versus 5.5%; P=0.2</td>
</tr>
<tr>
<td>Palmerini et al (152), 2006</td>
<td>Cohort, 2002–5</td>
<td>157/154</td>
<td>30-Day outcomes for PCI versus CABG: Death: 3.2% versus 4.5%; P=NS; MI: 4.5% versus 1.9%; P=NS; Revascularization: 0.6% versus 0.6%; P=NS</td>
<td>1-Year follow-up for PCI and CABG: Death: 13.4% versus 12.3%; 95% CI 0.51–1.77; P=0.6; MI: 8.3% versus 4.5%; 95% CI 0.21–1.32; P=0.17; Revascularization: 2.6% versus 25.5%; 95% CI 0.03–0.23; P=0.0001</td>
</tr>
<tr>
<td>Buszman et al (150), 2008</td>
<td>Randomized, 2001–4</td>
<td>52/53</td>
<td>30-Day outcomes for PCI versus CABG: Death: 0% versus 0%; MI: 2% versus 4%; P=NS; MACE: 2% versus 14%; 95% CI 0.79–0.99; P=0.03</td>
<td>1-Year follow-up for PCI versus CABG: Death: 2% versus 8%; P=NS; MI: 2% versus 6%; P=NS; Revascularization: 30% versus 10%; 95% CI 1.05–1.54; P=0.01; MACE: 32% versus 26%; 95% CI 0.85–1.38; P=NS</td>
</tr>
</tbody>
</table>
Appendix 6. Continued

<table>
<thead>
<tr>
<th>Reference, Year</th>
<th>Type of Study, Years of Recruitment</th>
<th>PCI/CABG</th>
<th>Short-Term Results</th>
<th>Long-Term Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sanmartin et al (154), 2007</td>
<td>Cohort, 2000–5</td>
<td>96/245</td>
<td>At 30 days for PCI versus CABG:</td>
<td>At 1 year, for PCI versus CABG:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Death: 2.1% versus 6.1%; ( P = 0.17 )</td>
<td>Death: 5.2% versus 8.4%; ( P = 0.37 )</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MI: 0% versus 1.3%; ( P = 0.44 )</td>
<td>Repeat revascularization: 5.2% versus 0.8%; ( P = 0.02 )</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Revascularization: 0.2% versus 0.0%; ( P = 0.03 )</td>
<td>Revascularization: 10.4% versus 11.4%; ( P = 0.5 )</td>
</tr>
<tr>
<td>Brener et al (156), 2008</td>
<td>Cohort with matched CABG controls, 1997–2006</td>
<td>97/190</td>
<td>At 3 years, outcomes for PCI versus CABG:</td>
<td>Death: 20% versus 15%; ( P = 0.14 )</td>
</tr>
<tr>
<td>Seung et al (139), 2008</td>
<td>Matched cohort, 2000–6</td>
<td>542/542</td>
<td>At 3 years, HRs for PCI versus CABG:</td>
<td>Death: 1.18; HR = 1.18; 95% CI 0.77–1.80; ( P = 0.45 )</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Death/MI/stroke: 1.10; HR = 1.10; 95% CI 0.75–1.62; ( P = 0.64 )</td>
<td>Revascularization: 4.76; HR = 4.76; 95% CI 2.80–8.11; ( P &lt; 0.001 )</td>
</tr>
<tr>
<td>White et al (155), 2008</td>
<td>Cohort, 2003–7</td>
<td>120/223</td>
<td>At 30 months, HRs for PCI versus CABG:</td>
<td>Death: 1.93; 95% CI 0.89–4.19; ( P = 0.10 )</td>
</tr>
<tr>
<td>Serruya et al (21), 2009</td>
<td>Randomized, 2005–7</td>
<td>348/357</td>
<td>At 1 year, HRs for PCI versus CABG:</td>
<td>Death/MI/CVA/revascularization: 15.8 versus 13.7; ( P = 0.44 )</td>
</tr>
</tbody>
</table>

CABG indicates coronary artery bypass graft surgery; CI, confidence interval; CVA, cerebrovascular accident; HR, hazard ratio; MACE, major adverse cardiac events; MI, myocardial infarction; NS, not significant; OR, odds ratio; RR, relative risk; and PCI, percutaneous coronary intervention.

When possible, 95% CIs reported were provided for RR, OR, or HR calculations along with probability values.

References


72. Deleté in proof.


KEY WORDS: ACCF/AHA practice guidelines  focused update  ST-elevation myocardial infarction  percutaneous coronary intervention  thienopyridines  parenteral anticoagulants  antiplatelet therapy  glycoprotein IIb/IIIa receptor antagonists.